

## Title

Systems-level patterns in biological processes are changed under longevity interventions and across biological age

## Authors

Kengo Watanabe<sup>1</sup>, Tomasz Wilmanski<sup>1</sup>, Priyanka Baloni<sup>1</sup>, Max Robinson<sup>1</sup>, Gonzalo G. Garcia<sup>2</sup>, Michael R. Hoopmann<sup>1</sup>, Mukul K. Midha<sup>1</sup>, David H. Baxter<sup>1</sup>, Michal Maes<sup>1</sup>, Seamus R. Morrone<sup>1</sup>, Kelly M. Crebs<sup>1</sup>, Charu Kapil<sup>1</sup>, Ulrike Kusebauch<sup>1</sup>, Jack Wiedrick<sup>3</sup>, Jodi Lapidus<sup>3</sup>, Jennifer C. Lovejoy<sup>1</sup>, Andrew T. Magis<sup>1</sup>, Christopher Lausted<sup>1</sup>, Jared C. Roach<sup>1</sup>, Gustavo Glusman<sup>1</sup>, Steven R. Cummings<sup>4,5</sup>, Nicholas J. Schork<sup>6,7</sup>, Nathan D. Price<sup>1,8</sup>, Leroy Hood<sup>1,\*</sup>, Richard A. Miller<sup>2,9</sup>, Robert L. Moritz<sup>1</sup>, and Noa Rappaport<sup>1,\*</sup>

## Affiliations

<sup>1</sup>Institute for Systems Biology, Seattle, WA 98109, USA.

<sup>2</sup>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.

<sup>3</sup>Oregon Health and Science University, Portland, OR 97239, USA.

<sup>4</sup>San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA.

<sup>5</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.

<sup>6</sup>Department of Quantitative Medicine, The Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.

<sup>7</sup>Department of Population Sciences and Molecular and Cell Biology, The City of Hope National Medical Center, Duarte, CA 91010, USA.

<sup>8</sup>Thorne HealthTech, New York, NY 10019, USA.

<sup>9</sup>University of Michigan Geriatrics Center, Ann Arbor, MI 48109, USA.

\*Correspondence to: Leroy Hood ([lee.hood@isbscience.org](mailto:lee.hood@isbscience.org)), Noa Rappaport ([noa.rappaport@isbscience.org](mailto:noa.rappaport@isbscience.org))

## Abstract

Aging manifests as progressive deterioration in cellular and systemic homeostasis, requiring systems-level perspectives to understand the gradual molecular dysregulation of underlying biological processes. Here, we report systems-level changes in the molecular regulation of biological processes under multiple lifespan-extending interventions in mice and across age in humans. In mouse cohorts, Differential Rank Conservation (DIRAC) analyses of liver proteomics and transcriptomics show that mechanistically distinct longevity interventions tighten the regulation of aging-related biological modules, including fatty acid metabolism and inflammation processes. An integrated analysis of liver transcriptomics with mouse genome-scale metabolic model supports the shifts in fatty acid metabolism. Additionally, the difference in DIRAC patterns between proteins and transcripts suggests biological modules which may be tightly regulated via cap-independent translation. In a human cohort spanning the majority of the adult lifespan, DIRAC analyses of blood proteomics and metabolomics demonstrate that regulation of biological modules does not monotonically loosen with age; instead, the regulatory patterns shift according to both chronological and biological ages. Our findings highlight the power of systems-level approaches to identifying and characterizing the biological processes involved in aging and longevity.

## 47 Introduction

48 Aging manifests as progressive deterioration in cellular and systemic homeostasis. In humans, it is  
49 accompanied by an increased risk for chronic conditions such as diabetes, heart disease,  
50 neurodegeneration, and cancer<sup>1,2</sup>. Interventions targeting aging mechanisms could delay or moderate  
51 chronic diseases and improve health and lifespan<sup>3</sup>. However, aging involves diverse chemical and  
52 physiological components, posing a challenge to comprehensive understanding<sup>4</sup>. For instance, many  
53 studies have demonstrated key roles of nutrient-sensing pathways in aging and longevity across  
54 species, including growth hormone (GH) and insulin/insulin growth factor 1 (IGF-1), AMP-activated  
55 protein kinase (AMPK), sirtuins, and mammalian (or mechanistic) target of rapamycin (mTOR)  
56 signaling pathways<sup>5-9</sup>, but these nutrient-sensing pathways are intricately interconnected with each  
57 other. Given the complex and multifaceted nature of aging, systems-level approaches may provide  
58 different perspectives from single molecule-level approaches and deepen our understanding of the  
59 aging processes.

60 Some nutritional and pharmacological interventions consistently extend lifespan and  
61 healthspan in mouse and other animal models<sup>3,10-12</sup>. Nutritional interventions include calorie  
62 restriction (CR)<sup>13</sup>, methionine restriction (MR)<sup>14</sup>, and ketogenic diet<sup>15,16</sup>. While the number of possible  
63 “geroprotectors” has been growing<sup>17</sup>, pharmacological interventions whose effects on lifespan  
64 extension were robustly confirmed by the National Institute on Aging (NIA) Interventions Testing  
65 Program (ITP)<sup>18</sup> include acarbose (ACA)<sup>19-21</sup>, canagliflozin<sup>22</sup>, 17 $\alpha$ -estradiol (17aE2)<sup>19,20,23</sup>, glycine<sup>24</sup>,  
66 nordihydroguaiaretic acid<sup>19,20,25</sup>, Protandim<sup>®</sup> (a Nrf2 inducer)<sup>20</sup>, and rapamycin (Rapa)<sup>26-28</sup>. Rapa is  
67 the only drug found to prolong lifespan in every organism studied, including yeast, worms, flies, and  
68 mammals<sup>29,30</sup>. Rapa modulates nutrient-sensing pathways by inhibiting the activity of mTOR through  
69 complex formation with FK506-binding protein 12, which globally attenuates protein translation via  
70 mTOR complex 1 (mTORC1) and ultimately reduces inflammation, increases autophagy, and  
71 improves stem cell maintenance<sup>31,32</sup>. ACA could potentially mimic some aspects of CR<sup>19</sup>; it is an oral  
72 antidiabetic drug which competitively inhibits the activity of  $\alpha$ -glucosidase enzymes to digest  
73 polysaccharides, resulting in the deceleration of sugar uptake in the gastrointestinal tract<sup>33</sup>. ACA  
74 treatment has been shown to extend lifespan in male mice more than in female mice<sup>19-21</sup>, possibly due  
75 to sex-dependent differences observed in heart, liver, and gut metabolite profiles<sup>34,35</sup>. 17aE2 is a  
76 stereoisomer of the dominant female sex hormone 17 $\beta$ -estradiol, having much weaker binding affinity  
77 to the classical estrogen receptors, stronger affinity to the brain estrogen receptor, and neuroprotective  
78 properties<sup>36,37</sup>. 17aE2 treatment extends lifespan in male but not in female mice<sup>19,20,23</sup>, potentially due  
79 to male-specific reduction of age-associated neuroinflammation<sup>38</sup> and sex-specific metabolomic  
80 responses observed in liver and plasma metabolite profiles<sup>39</sup>. Because these longevity drugs were  
81 tested with standardized protocols in NIA ITP and because they have differences in primary mode of  
82 action, comparisons of their effects on molecular regulation are valuable for our understanding of  
83 aging and longevity mechanisms.

84 Differential Rank Conservation (DIRAC) method quantifies systemic variability in gene  
85 expression within a module (i.e., a gene set, typically defined with an a priori network or pathway) for  
86 a given set of identically treated samples (called “phenotype”)<sup>40</sup>. Briefly, for a given module, the  
87 DIRAC algorithm first characterizes the rank consensus of each phenotype, which is represented by  
88 binary value set for pairwise gene pairs ( $i, j$ ) of the module to indicate whether the expression of  $i$ -th  
89 gene is higher than that of  $j$ -th gene in the phenotype-sharing samples. For each sample, the DIRAC  
90 algorithm next calculates the ratio of gene pairs whose relative ranking agrees with the rank consensus  
91 of the corresponding phenotype. Finally, the average of this ratio within the phenotype-sharing  
92 samples is a measure of how robustly the samples reflect the phenotypic gene expression pattern of  
93 the module. The module is considered “tightly” regulated within a phenotype when the samples vary  
94 little from their own consensus, because biological regulatory mechanisms or pressures must act  
95 consistently across the samples to produce such a high conservation pattern. In contrast, the module is  
96 considered “loosely” regulated within a phenotype when the samples vary considerably from their  
97 consensus, indicating a lack of conservation across the samples. For instance, a previous study  
98 applying DIRAC revealed the global loose regulation of BioCarta-defined modules in more malignant

99 phenotypes and later stages of disease progression<sup>40</sup>, indicating that a loss of tight regulation  
100 characterizes the dysregulation of biological processes in cancer. Hence, the DIRAC method can be  
101 used for identifying biological modules whose regulatory patterns are changed by longevity  
102 interventions or aging.

103 In this study, we report systems-level changes in the molecular regulation of biological  
104 processes, by jointly leveraging three omics datasets of mouse cohorts including the NIA ITP-  
105 confirmed longevity interventions and two omics datasets of a human cohort spanning the majority  
106 of the adult lifespan (Fig. 1). We apply DIRAC analysis to mouse liver protein abundance profiles,  
107 first with predefined modules derived from Gene Ontology Biological Process (GOBP) annotations  
108 and then with unbiased modules derived from Weighted Gene Co-expression Network Analysis  
109 (WGCNA)<sup>41,42</sup>, and demonstrate that three lifespan-extending drugs (ACA, 17aE2, and Rapa)  
110 promoted tighter regulation of aging-related modules, such as fatty acid metabolism and inflammation  
111 processes. As a complementary approach, mouse genome-scale metabolic model (GEM)<sup>43,44</sup> is  
112 developed with the three drugs-including liver transcriptomics<sup>45</sup>, and exhibits that multiple  
113 longevity interventions shifted fatty acid metabolism. In addition, comparisons of DIRAC analyses  
114 between the liver proteomics and transcriptomics suggest that biological modules were tightly  
115 regulated by the longevity interventions at different levels: transcription vs. post-transcription  
116 including the cap-independent translation (CIT) of specific mRNAs<sup>46</sup>. Finally, we explore the cross-  
117 sectional relationship between the tight module regulation and age in humans; DIRAC analyses of  
118 human plasma proteomics and metabolomics<sup>47,48</sup> reveal regulatory patterns of aging-related modules  
119 according to both chronological and biological ages<sup>48</sup>.

120

## 121 Results

### 122 Longevity interventions tightened the regulation of a priori proteomic modules

123 To compare the systems-level changes induced by different longevity interventions, we first  
124 applied DIRAC analysis to a liver proteomic dataset which was generated through a mouse  
125 longevity intervention experiment in the NIA Longevity Consortium (denoted “LC-M001  
126 proteomics”; Fig. 1). In this experiment, 48 mice were either untreated (Control) or subjected to one of  
127 three lifespan-extending drug treatments (ACA, 17aE2, or Rapa), and were euthanized at 12 months ( $n$   
128 = 12 (6 female, 6 male) mice per group). The design of evaluating drug effects on healthy young adult  
129 mice was motivated by the desire to reduce confounding effects of aging and of late-life diseases. In  
130 DIRAC analysis, we pooled female and male samples per intervention to calculate robust DIRAC rank  
131 consensus from small sample size, while recognizing the false negative risks for sex-dependent  
132 changes related to the sex-dependent effects of ACA and 17aE2 on lifespan extension<sup>19-21</sup>. For  
133 biological modules used in this DIRAC analysis, we prepared 164 a priori modules which were  
134 defined by the GOBP annotations mapped to the measured proteins (see Methods; Supplementary  
135 Data 1).

136 A DIRAC metric, rank conservation index (RCI)<sup>40</sup>, measures consistency in the relative  
137 abundance of biomolecules within a module among phenotype-sharing samples; high RCI indicates a  
138 strongly shared pattern of behavior (i.e., “tight” regulation), while low RCI indicates unpatterned  
139 behavior (i.e., “loose” regulation). ACA, 17aE2, and Rapa showed significantly higher RCI mean in  
140 the examined modules than Control (Fig. 2a), suggesting general tightening of module regulation by  
141 each of these longevity interventions. To identify the module changed (i.e., tightened or loosened)  
142 by any of the interventions, we assessed the intervention effect on RCI using Analysis of Variance  
143 (ANOVA) for each of the 164 modules. There were 12 significantly changed modules based on  
144 “conservatively” false discovery rate (FDR)-adjusted  $P < 0.05$  (see Methods; cf. 51 modules exhibited  
145 nominal  $P < 0.05$ ; Fig. 2b). Among these 12 changed modules, the post hoc RCI comparisons between  
146 Control and each intervention group revealed that seven, nine, and eight modules were significantly  
147 tightened by ACA, 17aE2, and Rapa, respectively (Fig. 2c), while no module was loosened. Four  
148 modules were significantly tightened under all the three interventions (Fig. 2c), which were  
149 functionally related to fatty acid  $\beta$ -oxidation (GO:0006635, GO:0031998) or protein-transporting to

150 peroxisomes (GO:0016558, GO:0006625) (Fig. 2d, Supplementary Fig. 1c). Given that the primary  
151 mode of action is different between the studied drugs, this result suggests that systems-level regulation  
152 for these biological processes may be a general mechanism for lifespan extension.

153 Although high RCI reflects a shared pattern of relative abundances within the phenotype and  
154 implies biological regulation required for the pattern, a tightly regulated module may still exhibit  
155 different relative abundance patterns under different phenotypes. Another DIRAC metric, rank  
156 matching score (RMS)<sup>40</sup>, allows us to compare relative abundance patterns between phenotypes, by  
157 measuring the similarity of each sample to the consensus pattern of a certain phenotype rather than  
158 measuring the consistency to the consensus pattern of the sample's own phenotype (i.e., RCI). For  
159 instance, in *acetyl-CoA biosynthetic process from pyruvate* (GO:0006086) where higher RCI against  
160 Control was observed significantly in ACA and 17aE2 and as a tendency in Rapa (Supplementary Fig.  
161 1a), Rapa and ACA showed significantly higher and tendentially lower mean of RMSs, respectively,  
162 than Control under the 17aE2 rank consensus (Supplementary Fig. 1b), suggesting that Rapa changed  
163 this module similarly to 17aE2 while ACA did dissimilarly. Moreover, this Rapa's RMS mean was  
164 comparable to 17aE2's RMS mean under the 17aE2 rank consensus (i.e., corresponding to 17aE2's  
165 RCI) (Supplementary Fig. 1b). These DIRAC patterns suggest two modes of tight regulation for this  
166 module: one under ACA and the other under 17aE2 and Rapa. Thus, using RMS under each group's  
167 rank consensus, we explored the similarly tightened modules across the interventions. Among the  
168 seven, nine, and eight significantly tightened modules by ACA, 17aE2, and Rapa, three, four, and two  
169 modules were similarly changed by the other two interventions, respectively (Fig. 2c). In particular,  
170 the four consistently tightened modules across the interventions (Fig. 2c, d, Supplementary Fig. 1c)  
171 exhibited significantly higher mean of RMSs in intervention groups compared to Control under almost  
172 all the other intervention group's rank consensus (e.g., 17aE2 and Rapa showed significantly higher  
173 RMS mean than Control under the ACA rank consensus; Fig. 2e, Supplementary Fig. 1d), suggesting  
174 that fatty acid  $\beta$ -oxidation and peroxisome transport were similarly tightened by mechanistically  
175 distinct prolongevity interventions and thus may be a general mechanism contributing to longevity.

176 Taken together, these results suggest that prolongevity interventions generally tightened the  
177 regulation of the examined proteomic modules and, in the modules related to fatty acid  $\beta$ -oxidation  
178 and peroxisome transport, the tightened protein expression profile was similar between different  
179 drugs.  
180

### 181 **Prolongevity interventions tightened the regulation of data-driven proteomic modules**

182 Given potential biases in the module definitions with GOBP terms, we inferred data-driven modules  
183 using an unsupervised clustering approach, WGCNA<sup>41,42</sup>. WGCNA identifies modules of highly  
184 interconnected biomolecules, relying on the overall correlation network computed from high-  
185 dimensional data. We applied WGCNA to the LC-M001 proteomics and identified nine modules,  
186 ranging in size from 66 to 839 proteins (Fig. 3a). Each WGCNA module can be characterized by the  
187 "module eigengene" (i.e., the first principal component (PC) of the protein abundance matrix for the  
188 module)<sup>42</sup>. To identify the module associated with any of the interventions out of the nine data-driven  
189 modules, we assessed the intervention effect on the module eigengene for each module using ANOVA  
190 model with intervention, sex, and intervention–sex interaction terms. There were no significant  
191 interaction effects in any of the nine modules, and only one module, denoted Darkgreen, exhibited a  
192 significant intervention effect ( $P = 0.00082$  after the Bonferroni adjustment). The post-hoc  
193 comparison revealed that 17aE2 and Rapa, but not ACA, showed significantly higher value of the  
194 module eigengene than Control in the Darkgreen module (Fig. 3b, c), suggesting that the expression  
195 profile of the Darkgreen module was changed specifically by 17aE2 and Rapa.

196 WGCNA fits a "scale-free" network topology where the majority of nodes share relatively  
197 few edges with other nodes, while the central nodes that have high intramodular connectivity (called  
198 "hub" nodes) frequently take essential functions in the system<sup>49</sup>. To better understand how 17aE2 and  
199 Rapa changed the Darkgreen module structure, we assessed the relationship between the intervention  
200 effect on each protein in the Darkgreen module and their respective intramodular connectivity (see

201 Methods). The intervention effect on each protein showed significant positive correlation with  
202 intramodular connectivity (Spearman's  $\rho = 0.50$ ,  $P = 2.05 \times 10^{-52}$ , Fig. 3d), suggesting that  
203 intramodular hub proteins were more strongly affected by the interventions than less connected  
204 proteins. Interestingly, 18 of the top 30 hub proteins in the Darkgreen module were mitochondrial  
205 proteins, involved in tricarboxylic acid (TCA) cycle metabolism and oxidative phosphorylation (Fig.  
206 3e). Furthermore, prohibitin 1 (PHB1) and PHB2, 2 of the top 10 hub proteins, form the mitochondrial  
207 PHB complex, which is known to regulate fatty acid oxidation and assembly of mitochondrial  
208 respiratory complexes<sup>50,51</sup>, as well as to affect lifespan in *C. elegans*<sup>52</sup>. Collectively, our results from  
209 WGCNA revealed coordinated changes in the expression profiles of mitochondrial liver proteins that  
210 were limited to two (17aE2 and Rapa) of the three studied drugs.

211 We subsequently re-analyzed the LC-M001 proteomics data using the DIRAC method with  
212 seven of the nine WGCNA-identified modules (see Methods; Fig. 3a, Supplementary Data 2). ACA,  
213 17aE2, and Rapa showed significantly higher RCI mean in the examined modules than Control (Fig.  
214 3f), suggesting general tightening of module regulation by each of these prolongevity interventions,  
215 consistent with the initial DIRAC result based on GOBP terms (Fig. 2a). Additionally, all the seven  
216 WGCNA modules exhibited significant intervention effects on RCI in ANOVA (FDR-adjusted  $P <$   
217  $0.05$ ; Fig. 3g) and significantly higher RCI in any intervention group compared to Control in the post  
218 hoc RCI comparisons (Fig. 3g, h), suggesting that all the WGCNA modules were consistently  
219 tightened across ACA, 17aE2, and Rapa. Moreover, the Darkgreen module exhibited significantly  
220 higher mean of RMSs in intervention groups compared to Control under almost all the other  
221 intervention group's rank consensus (e.g., 17aE2 and Rapa showed significantly higher RMS mean  
222 than Control under the ACA rank consensus; Fig. 3i), suggesting that the tightly regulated patterns are  
223 similar between the three drugs. At the same time, Rapa's RMS mean was more similar to 17aE2's  
224 RMS mean than to ACA's RMS mean (e.g., 17aE2 showed higher RMS mean than ACA under the  
225 Rapa rank consensus) in the Darkgreen module (Fig. 3i), implying a difference in the tightly regulated  
226 pattern between ACA vs. 17aE2 and Rapa, in line with their effects on module expression profiles  
227 (Fig. 3b). Note that, if the tightly regulated pattern of ACA was completely different from those of  
228 17aE2 and Rapa, ACA could have showed lower RMS mean than Control under the 17aE2 or Rapa  
229 rank consensus (cf. Supplementary Fig. 1b).

230 These findings suggest that the Darkgreen module was tightly regulated across all the three  
231 interventions, while also exhibiting intervention-specific effects on protein expression profiles related  
232 to mitochondrial energy metabolism. Altogether, our results indicate that the tightening of module  
233 regulation was a general signature of the prolongevity interventions within the measured proteomic  
234 space.  
235

### 236 **Prolongevity interventions shifted the flux regulation in fatty acid metabolism**

237 As a complementary approach to the findings from DIRAC and WGCNA analyses, we performed in  
238 silico analysis using the mouse GEM<sup>43</sup> to investigate metabolic shifts associated with prolongevity  
239 interventions. GEM is a mathematical framework that leverages knowledge-base cataloging  
240 information about biochemical reactions within a system (e.g., single cell, tissue, organ), including  
241 metabolites, genes encoding catalytic enzymes, and their stoichiometry<sup>44</sup>. Using optimization  
242 techniques with large-scale experimental data (e.g., transcriptomics), the solved stoichiometric  
243 coefficients of each reaction allow flux prediction for metabolic reactions in the system at  
244 equilibrium<sup>53</sup>. Thus, GEM has been used to investigate metabolic changes in various systems and  
245 specific contexts (e.g., human cancers)<sup>54</sup>. Since the detected proteins in the LC-M001 proteomics did  
246 not sufficiently cover the metabolic proteins included in the mouse GEM, we utilized a mouse liver  
247 transcriptomic dataset from a previous prolongevity intervention study<sup>45</sup> (referred as "M001-related  
248 transcriptomics"; Fig. 1), whose experimental design resembled the LC-M001 experiment and  
249 contained ACA, 17aE2, and Rapa treatments as prolongevity interventions. In this M001-related  
250 experiment, 78 mice were prepared for either control or one of the prolongevity interventions,  
251 including two genetically modified models (the growth hormone receptor knockout mouse (GHRKO)

252 and the hypopituitary Snell dwarf mouse (SnellDW)), two nutritional interventions (CR and MR), and  
253 four pharmacological interventions (ACA, 17aE2, Protandim, and Rapa), and were euthanized at  
254 young adult ages depending on the intervention type ( $n = 3\text{--}12$  mice per intervention group; see  
255 Methods). By integrating the M001-related transcriptomics with the mouse generic GEM<sup>43</sup> for each of  
256 78 samples, we generated 78 “context-specific” metabolic networks (i.e., GEMs constrained by each  
257 sample condition), and subsequently predicted flux values of the metabolic reactions for each context-  
258 specific GEM (see Methods). As a result, the flux values were successfully predicted for 7,930  
259 reactions among the 10,612 reactions defined in the generic GEM (Supplementary Data 3).

260 To identify the reaction changed by any of the interventions, we assessed the intervention  
261 effect on the flux value using Kruskal–Wallis  $H$ -test for each of the 7,930 reactions. To mitigate the  
262 small sample size, we pooled samples per intervention in this analysis, while recognizing the false  
263 negative risks for age and sex-dependent changes related to the sex-dependent effects of ACA, 17aE2,  
264 and Protandim on lifespan extension<sup>19–21</sup>. There were 1,822 significantly changed reactions based on  
265 “conservatively” FDR-adjusted  $P < 0.05$  (see Methods; cf. 2,156 reactions exhibited nominal  $P <$   
266 0.05; Fig. 4a). Among these 1,822 changed reactions, the post hoc comparisons of flux values between  
267 each intervention group and its corresponding control group revealed that 9, 1, 730, 851, and 1,015  
268 reactions were significantly changed by ACA, Rapa, MR, GHRKO, and SnellDW, respectively (Fig.  
269 4a–c), while no reaction was significantly changed by 17aE2, Protandim, and CR. We observed that  
270 many of these changed reactions belonged to several specific “subsystems”, analogous to the  
271 functional pathways, in the GEM system. For instance, when we focused on the central energy  
272 metabolism, 8 of the 10 changed reactions belonged to the *fatty acid oxidation* subsystem and  
273 exhibited the concordant direction of flux change across interventions (Fig. 4d). However, it was  
274 possible that the frequency of observed subsystems in the changed reactions was merely dependent on  
275 the number of mapped reactions to the subsystem, which is largely different between subsystems<sup>43</sup>.  
276 Hence, to interpret which subsystems in GEM were shifted by longevity interventions, we further  
277 performed overrepresentation analysis on the significantly changed reactions of ACA, MR, GHRKO,  
278 and SnellDW. Among the 5, 53, 60, and 57 tested subsystems that were annotated to any of the  
279 changed reactions, 0, 5, 13, and 11 subsystems were significantly enriched in the changed reactions of  
280 ACA, MR, GHRKO, and SnellDW, respectively (FDR-adjusted  $P < 0.05$ ; Fig. 4e, Supplementary Fig.  
281 2a, b, Supplementary Data 4). In particular, the *biotin metabolism*, *cholesterol metabolism*, *fatty acid*  
282 *oxidation*, and *fatty acid synthesis* subsystems were consistently enriched across MR, GHRKO, and  
283 SnellDW (Fig. 4e, Supplementary Fig. 2a, b), suggesting that these biological processes were shifted  
284 at the systems level by mechanistically distinct longevity interventions.

285 Given that MR has been often discussed as if it was a form of CR, we addressed the  
286 difference in reaction flux between CR and MR. Among the 1,822 reactions changed by any of the  
287 interventions, the post hoc comparisons of flux values among CR, MR, and their corresponding  
288 control groups revealed that 0, 1,081, and 1,229 reactions were significantly different in CR vs.  
289 control, MR vs. control, and MR vs. CR, respectively (Supplementary Fig. 2c–f). Overrepresentation  
290 analysis revealed that 11 subsystems were significantly enriched in the different reactions between CR  
291 and MR (FDR-adjusted  $P < 0.05$ ; Supplementary Fig. 2g), implying that MR shifted these subsystems  
292 at the systems level in a different manner from CR.

293 In summary, our in silico analysis differentiated the metabolic effects of different  
294 longevity interventions, and implied that multiple longevity interventions concordantly shifted  
295 fatty acid metabolism at the systems level.  
296

### 297 **Prolongevity interventions likely tightened the module regulation partly through cap-** 298 **independent translation**

299 To further investigate the tightening effects of longevity interventions on proteomic modules (Fig.  
300 2, 3), we applied DIRAC analysis to the M001-related transcriptomics<sup>45</sup>. Again, we pooled samples  
301 per intervention to calculate robust DIRAC rank consensus, and analyzed only three longevity  
302 interventions (ACA, Rapa, and CR) and their corresponding control (Control) based on sample size ( $n$

303 = 12 (6 female, 6 male) mice per group). Using 3,747 a priori modules defined by the GOBP  
304 annotations mapped to the measured transcripts (see Methods; Supplementary Data 5), we found that  
305 ACA, Rapa, and CR showed significantly higher RCI mean in the examined modules than Control  
306 (Fig. 5a). This result suggests the general tightening of module regulation within the measured  
307 transcriptomic space, as well as within the measured proteomic space (Fig. 2a, 3f). We next assessed  
308 the intervention effect on RCI using ANOVA for each of the 3,747 modules, and identified 1,829  
309 significantly changed modules by any of the interventions based on “conservatively” FDR-adjusted  $P$   
310  $< 0.05$  (see Methods; cf. 2,107 modules exhibited nominal  $P < 0.05$ ; Supplementary Fig. 3a). Among  
311 these 1,829 changed modules, the post hoc RCI comparisons between Control and each intervention  
312 group revealed that 828, 432, and 1,789 modules were significantly tightened by ACA, Rapa, and CR,  
313 respectively (Supplementary Fig. 3a), while no module was loosened. Subsequently, using RMS under  
314 each group’s rank consensus, we explored the similarly tightened modules across the interventions.  
315 Among the 828, 432, and 1,789 significantly tightened modules by ACA, Rapa, and CR, 35, 19, and  
316 12 modules were similarly changed by the other two interventions, respectively (Supplementary Fig.  
317 3b). For instance, *ubiquitin-dependent protein catabolic process* (GO:0006511), a consistently  
318 tightened module across the interventions (Supplementary Fig. 3c), exhibited significantly higher  
319 mean of RMSs in intervention groups compared to Control under almost all the other intervention  
320 group’s rank consensus (e.g., Rapa and CR showed significantly higher RMS mean than Control  
321 under the ACA rank consensus; Supplementary Fig. 3d), suggesting that this module was similarly  
322 tightened in transcripts by mechanistically distinct longevity interventions.

323 To directly compare the DIRAC results between the LC-M001 proteomics and the M001-  
324 related transcriptomics, we focused on the two interventions (ACA and Rapa) and the 147 GOBP  
325 modules that were used in both omics results (Supplementary Data 6), and re-assessed the intervention  
326 effect on RCI using ANOVA for each of the 147 modules and each omics. There were 10 and 5  
327 significantly changed modules by any of the interventions in proteins and transcripts, respectively,  
328 based on “conservatively” FDR-adjusted  $P < 0.05$  (see Methods). Among these changed modules, the  
329 post hoc RCI comparisons between Control and each intervention group revealed that 8, 6, 10, and 4  
330 modules were significantly tightened by ACA in proteins, ACA in transcripts, Rapa in proteins, and  
331 Rapa in transcripts, respectively (Fig. 5b). Interestingly, the modules that were significantly tightened  
332 by ACA and Rapa in both proteins and transcripts were three modules related to fatty acid  $\beta$ -oxidation  
333 (GO:0006635), retrograde transport (GO:1990126), or interleukin 7 (GO:0098761) (Fig. 5b, c). This  
334 result suggests that these modules were tightened by the longevity interventions via transcription-  
335 level changes with concordant changes of proteomic profiles. At the same time, we also observed  
336 seven modules which were tightened specifically in proteins (Fig. 5b). In particular, *tryptophan*  
337 *catabolic process to kynurenine* (GO:0019441) exhibited significantly higher RCI across interventions  
338 compared to Control specifically in proteins (Fig. 5d), suggesting that this module was tightened by  
339 ACA and Rapa in the proteomic profile but not in the transcriptomic profile. This inconsistency may  
340 reflect post-transcriptional regulatory mechanisms that can affect protein profiles beyond  
341 transcriptional changes. For instance, since the abundance of a protein is determined by both its  
342 synthesis and degradation rates, a difference in “proteostasis”, whose loss is known as an aging  
343 signature<sup>1,55</sup>, can lead to the change in protein abundance without a change in transcript abundance.

344 Likewise, CIT<sup>46</sup> can be a possible post-transcriptional mechanism to explain the inconsistency  
345 between proteins and transcripts. In contrast to the standard cap-dependent translation, CIT does not  
346 require the interaction of the eukaryotic initiation factor 4E (eIF4E) complex with 5’ cap of mRNA;  
347 N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification in 5’ untranslated regions of mRNA can trigger the  
348 recruitment of specific initiation and elongation factors, followed by the selective translation of m<sup>6</sup>A-  
349 tagged mRNAs. Previous studies have shown the upregulated translation of a subset of mRNAs via  
350 CIT in long-lived endocrine mutant mice<sup>56</sup> and similar increases of CIT in mice treated with ACA,  
351 17aE2, or Rapa<sup>57</sup>. We therefore tested if CIT could explain the difference in module regulation  
352 between proteins and transcripts, by jointly applying DIRAC analysis to the LC-M001 proteomics and  
353 another liver proteomic dataset which was generated through a mouse CIT experiment (denoted “LC-  
354 M004 proteomics”; Fig. 1). In this experiment, 16 mice were treated with either solvent (Control-2) or

355 4EGI-1, a synthetic small compound which inhibits the eIF4E–eIF4G interaction and thereby blocks  
356 cap-dependent translation and enhances CIT<sup>58</sup>, and were euthanized at young adult ages ( $n = 8$  (4  
357 female, 4 male) mice per group). To directly compare the DIRAC results across the LC-M001 and  
358 LC-M004 proteomics, we focused on 153 GOBP modules for this analysis, which were mapped to the  
359 measured proteins in both datasets (see Methods; Supplementary Data 7). Consistent with the elevated  
360 module tightness in ACA, 17aE2, and Rapa against their corresponding control (Control-1), 4EGI-1  
361 showed significantly higher RCI mean in the examined modules compared to Control-2 (Fig. 5e),  
362 implying general tightening of module regulation by the CIT enhancement. To reveal the similarity of  
363 module regulation between prolongevity interventions and 4EGI-1, we calculated RMSs under the  
364 rank consensus of Control-2 and 4EGI-1 for the LC-M001 groups (Control-1, ACA, 17aE2, and  
365 Rapa), and assessed the intervention effect on the RMS mean using ANOVA for each of the 153  
366 modules and each rank consensus. There were four and seven significantly changed modules by any  
367 of the interventions under the Control-2 and 4EGI-1 rank consensus, respectively, based on  
368 “conservatively” FDR-adjusted  $P < 0.05$  (see Methods; cf. 24 and 41 modules exhibited nominal  $P <$   
369  $0.05$ , respectively). Among these seven changed modules under the 4EGI-1 rank consensus, the post  
370 hoc comparisons for the RMS mean between Control-1 and each intervention group revealed that two,  
371 one, and three modules were changed “dissimilarly” to the 4EGI-1 consensus by ACA, 17aE2, and  
372 Rapa, respectively (Supplementary Fig. 3e). For instance, in *RIG-I signaling pathway* (GO:0039529),  
373 all the ACA, 17aE2, and Rapa showed significantly lower mean of RMSs than Control-1 under the  
374 4EGI-1 consensus (Supplementary Fig. 3f). Given that this module was similarly tightened across the  
375 interventions in proteins (Supplementary Fig. 1e, f) while ACA and Rapa did not show the significant  
376 RCI difference from control in transcripts (Supplementary Fig. 3g), this result suggests that *RIG-I*  
377 *signaling pathway* may be tightened in proteins via post-transcriptional regulation other than CIT. In  
378 contrast, the post hoc RMS mean comparisons for the seven changed modules also revealed that two  
379 modules were changed “similarly” to the 4EGI-1 consensus by 17aE2 (Fig. 5f); e.g., *mitochondrial*  
380 *ATP synthesis coupled proton transport* (GO:0042776) exhibited significantly higher mean of RMSs  
381 in 17aE2 compared to Control-1 (Supplementary Fig. 3h). Because the regulatory pattern of 17aE2 in  
382 transcripts was not available and because our  $P$ -value adjustment for multiple hypotheses was  
383 conservative (see Methods), we also checked the 41 changed modules based on nominal  $P < 0.05$   
384 under the 4EGI-1 rank consensus. The post hoc RMS mean comparisons for these 41 changed  
385 modules revealed that four and three modules were changed “similarly” to the 4EGI-1 consensus by  
386 17aE2 and Rapa, respectively (Fig. 5f). Remarkably, in *coding region instability determinant (CRD)-*  
387 *mediated mRNA stabilization* (GO:0070934) and *positive regulation of RNA polymerase II*  
388 *transcription preinitiation complex (PIC) assembly* (GO:0045899), Rapa showed significantly higher  
389 mean of RMSs than Control-1 under the 4EGI-1 rank consensus (Fig. 5g, Supplementary Fig. 3i),  
390 while Rapa did not show the significant RCI difference from control in transcripts (Fig. 5h,  
391 Supplementary Fig. 3j), suggesting that regulation of these processes was modified by Rapa likely via  
392 CIT.

393 Altogether, these findings suggest that the tightening of module regulation was a general  
394 signature of the prolongevity interventions even within the measured transcriptomic space and that the  
395 tightened modules in proteins were achieved through both transcriptional and post-transcriptional  
396 regulation, potentially including augmented CIT.

397

### 398 **Module regulation was changed across chronological and biological ages**

399 Our results observed in mice demonstrate that the molecular regulation of biological processes is  
400 modifiable at the systems level. To address the systems-level dynamics through lifetime in humans,  
401 we investigated the cross-sectional relationship between the tight module regulation and age by  
402 applying DIRAC analysis to a plasma proteomic dataset which was collected through the Arivale  
403 program<sup>47,48</sup> (Fig. 1). This cohort consisted of community-dwelling adults ranging from 18 to 89 years  
404 old, who were not screened for any particular disease, and we stratified this cohort into deciles per sex  
405 by chronological age (referred as “CA10”; Supplementary Fig. 4a). Setting these CA10 groups as the  
406 group unit for the rank consensus, we calculated DIRAC metrics for 19 a priori modules which were



407 defined by the GOBP annotations mapped to the measured proteins (see Methods; Supplementary  
408 Data 8). The RCI median in the examined modules gradually decreased along an aging gradient in  
409 younger groups, while this overall trend was reversed in older groups (Fig. 6a). We randomized the  
410 sample–group correspondence to calculate an empirical null-hypothesis distribution, and confirmed  
411 that the RCI median was significantly higher than expected in almost all the CA10 groups  
412 (Supplementary Fig. 4b), suggesting that the examined modules were generally under the tight  
413 regulation especially in the youngest group (Q1) and the oldest group (Q10). Next, we compared the  
414 similarity of module regulation across chronological age using RMS under the Q1 or Q10 rank  
415 consensus. The module RMS mean showed significant negative and positive correlations with the  
416 quantile order of CA10 groups under the Q1 and Q10 rank consensus, respectively (Spearman’s  $\rho =$   
417  $-0.78$  (Q1, female),  $-0.40$  (Q1, male),  $0.70$  (Q10, female),  $0.60$  (Q10, male); Fig. 6b), suggesting that  
418 module regulation was generally more similar between closer CA10 groups and the regulatory  
419 patterns were vastly dissimilar between Q1 and Q10. To identify the module whose regulation  
420 similarity to Q1 or Q10 was associated with chronological age, we regressed the RMS under the Q1 or  
421 Q10 consensus to chronological age with Body Mass Index (BMI) and ancestry PCs as covariates for  
422 each of the 19 modules, each rank consensus, and each sex. There were 18 and 13 modules exhibiting  
423 a significant negative association under the Q1 rank consensus and 17 and 18 modules exhibiting a  
424 significant positive association under the Q10 rank consensus for female and male, respectively, based  
425 on “conservatively” FDR-adjusted  $P < 0.05$  (see Methods; Fig. 6c). For instance, *neutrophil*  
426 *chemotaxis* (GO:0030593) exhibited significant negative and positive associations of the RMS with  
427 chronological age in both sexes under the Q1 and Q10 rank consensus, respectively (Fig. 6d),  
428 suggesting that this module was gradually changed across chronological age and its regulatory pattern  
429 was vastly dissimilar between younger and older individuals. These results suggest that the general  
430 tightness of module regulation decreased with chronological age up until midlife but then increased  
431 during older stage and that the tight patterns of module regulation were different between younger and  
432 older individuals.

433 To validate these findings in another dimensional space, we performed DIRAC analysis on a  
434 plasma metabolomic dataset of the Arivale cohort (Fig. 1). Since the dataset availability was different  
435 between participants, we re-defined CA10 groups for this analysis (Supplementary Fig. 5a). Because  
436 functional annotations to define metabolite modules are limited, we used the nine data-driven  
437 metabolomic modules identified by WGCNA (Supplementary Fig. 5b, Supplementary Data 9). Again,  
438 the RCI median in the examined modules exhibited the “U-shaped” transition with respect to CA10  
439 group (Supplementary Fig. 5c), and the module RMS mean showed significant negative and positive  
440 correlations with the quantile order of CA10 groups under the Q1 and Q10 rank consensus,  
441 respectively (Spearman’s  $\rho = -0.90$  (Q1, female),  $-0.76$  (Q1, male),  $0.87$  (Q10, female),  $0.66$  (Q10,  
442 male); Supplementary Fig. 5d). Subsequently, we regressed the RMS under the Q1 or Q10 consensus  
443 to chronological age with BMI and ancestry PCs as covariates for each of the nine modules, each rank  
444 consensus, and each sex. All the nine modules exhibited significant negative and positive associations  
445 under the Q1 and Q10 rank consensus for both sexes, respectively, based on FDR-adjusted  $P < 0.05$   
446 (Supplementary Fig. 5e, f). Therefore, in line with the examined proteomic space, the similar  
447 associations between the tightness of module regulation and chronological age were observed in the  
448 examined metabolomics space.

449 Previously, a multiomic estimate for chronological age (biological age) has been calculated  
450 for the Arivale cohort<sup>48</sup>. Importantly, the difference between chronological and biological ages ( $\Delta$  age)  
451 was a more accurate metric of wellness than chronological age (i.e., negative and positive  $\Delta$  ages  
452 indicated healthier and unhealthier conditions than chronologically expected, respectively) and  
453 modifiable (i.e., lifestyle intervention decreased  $\Delta$  age). Hence, we further explored the relationships  
454 between module regulation and health conditions by re-performing DIRAC analysis on the Arivale  
455 proteomics with  $\Delta$  age-stratified groups; we divided the Arivale cohort into tertiles per sex by  
456 chronological age (referred as “CA3”) and further stratified each CA3 group into five subgroups by  $\Delta$   
457 age (referred as “DA5”); Fig. 6e, Supplementary Fig. 4c). Under the rank consensus of the most  
458 negative  $\Delta$  age subgroup in young CA3 group (Y-subQ1) and the most positive  $\Delta$  age subgroup in old

459 CA3 group (O-subQ5), the module RMS mean showed significant negative and positive correlations  
460 with the quantile order of DA5 subgroups in young and old CA3 groups, respectively (Spearman's  $\rho =$   
461  $-0.42$  (Y-subQ1, young female),  $-0.56$  (Y-subQ1, young male),  $0.51$  (O-subQ5, old female),  $0.60$  (O-  
462 subQ5, old male); Fig. 6f). Moreover, these negative and positive correlations between the module  
463 RMS mean and the quantile order of DA5 subgroups under the Y-subQ1 and O-subQ5 rank  
464 consensus, respectively, were observed in the other CA3 groups as a tendency or with statistical  
465 significance based on the Holm–Bonferroni adjustment (Fig. 6f). These results suggest that module  
466 regulation was generally more similar between closer DA5 groups and the regulatory patterns were  
467 vastly dissimilar between Y-subQ1 and O-subQ5. To identify the module whose regulation similarity  
468 to Y-subQ1 or O-subQ5 was associated with  $\Delta$  age, we regressed the RMS under the Y-subQ1 or O-  
469 subQ5 consensus to  $\Delta$  age with chronological age, BMI, and ancestry PCs as covariates for each of the  
470 19 modules, each rank consensus, each sex, and each CA3 group. There were 11, 7, 6, 13, 1, and 4  
471 modules exhibiting a significant negative association under the Y-subQ1 rank consensus and 5, 10, 9,  
472 7, 1, and 10 modules exhibiting a significant positive association under the O-subQ5 rank consensus  
473 for female young, female middle, female old, male young, male middle, and male old CA3 groups,  
474 respectively, based on “conservatively” FDR-adjusted  $P < 0.05$  (see Methods; Fig. 6g). For instance,  
475 *neutrophil chemotaxis* (GO:0030593) exhibited significant negative and positive associations of the  
476 RMS with  $\Delta$  age in both sexes and all the CA3 groups, except for male middle CA3 group, under the  
477 Y-subQ1 and O-subQ5 rank consensus, respectively (Supplementary Fig. 4d), suggesting that this  
478 module was gradually changed across  $\Delta$  age and its regulatory pattern was vastly dissimilar between  
479 biologically younger and biologically older individuals. Likewise, we re-performed DIRAC analysis  
480 on the Arivale metabolomics with  $\Delta$  age-stratified groups, and observed the same association patterns  
481 between the RMS under the Y-subQ or O-subQ5 rank consensus and  $\Delta$  age (Supplementary Fig. 6).

482 Altogether, these results imply that the regulatory patterns of proteomic and metabolomic  
483 modules shifted depending on both chronological and biological ages and that the tight module  
484 regulation representatively corresponded to a healthier state in the young stage but an unhealthier state  
485 in the old stage.  
486

## 487 Discussion

488 Studies in invertebrate organisms and mice have shown multiple ways to extend lifespan and postpone  
489 age-related diseases<sup>3,10–12</sup>. Aging can be slowed, and healthspan can be extended, by mutation of  
490 individual genes, dietary restrictions, or oral administration of compounds. Data are becoming  
491 available to determine which of the many cellular and molecular traits modified by each of these  
492 interventions are shared across slow-aging models and which are less universal. Elucidation of the  
493 physiological and cellular mechanisms of effective interventions will provide clues for possible  
494 measures to improve human health and may also give useful prognostic information. In this study, we  
495 demonstrated the following key findings: (1) longevity interventions generally tightened the  
496 systems-level regulation of biological processes at both transcriptional and post-transcriptional layers  
497 in mice; (2) fatty acid metabolism emerged as a common process shifted by multiple longevity  
498 interventions; (3) the systems-level regulation of biological processes was associated with both  
499 chronological and biological ages in humans.

500 By leveraging mouse omics datasets and systems-level approaches, we demonstrated that  
501 longevity interventions modified biological processes and metabolic reactions at the systems level  
502 (Fig. 2–5). In particular, DIRAC analyses revealed that the tightening of module regulation was a  
503 general signature of the longevity interventions within the measured proteomic and transcriptomic  
504 spaces (Fig. 2a, 3f, 5a). Interestingly, a previous study using DIRAC revealed the general loosening of  
505 module regulation in more malignant phenotypes and later stages of cancer progression<sup>40</sup>. Given that  
506 cancer resistance and longevity share commonality in mechanisms such as DNA repair and telomere  
507 maintenance<sup>55,59</sup>, aging may be promoted, in part, by loss of tight regulation for pertinent modules,  
508 and its tightness maintenance may be a key longevity strategy. Furthermore, we identified at least 12  
509 proteomic modules (Fig. 2b, Supplementary Data 1), 1,829 transcriptomic modules (Supplementary

510 Fig. 3a, Supplementary Data 5), and 1,822 reactions (Fig. 4a, Supplementary Data 3) affected by any  
511 of the longevity interventions. These modules and reactions included the biological processes  
512 highly related to “aging hallmarks”<sup>55</sup> and “pillars of aging”<sup>1</sup>, such as amino acid regulation, fatty acid  
513 regulation, TCA cycle, stress response, and inflammation, consistent with the proposed roles of these  
514 processes in aging<sup>6-9,55</sup>. Therefore, our current study showed the power of systems-level approaches to  
515 explore and test hypotheses about the control of aging and longevity in mammals, and provided a  
516 translational implication that potential longevity interventions may be identified and evaluated  
517 based on their regulatory effects on these systems.

518 Fatty acid  $\beta$ -oxidation is the catabolic process of fatty acid breakdown for energy production,  
519 with mitochondria and peroxisomes being the major involved organelles<sup>60</sup>. We demonstrated that fatty  
520 acid  $\beta$ -oxidation was tightened in both proteins and transcripts consistently across mechanistically  
521 distinct longevity interventions (Fig. 2d, 5c). We also observed that the system transporting  
522 proteins into peroxisomes was tightened in proteins consistently across the interventions  
523 (Supplementary Fig. 1c), and implied the possibility that some aspects of mitochondrial functions  
524 were affected by 17aE2 and Rapa (Fig. 3e). Moreover, we showed that reactions involved in fatty acid  
525 synthesis and oxidation were concordantly shifted across MR, GHRKO, and SnellDW (Fig. 4d, e,  
526 Supplementary Fig. 2a, b). All these findings support the conclusion that fatty acid  $\beta$ -oxidation was  
527 directed towards tight control in a whole cellular system for longevity. At the same time, this systems-  
528 level control of fatty acid  $\beta$ -oxidation was observed quite possibly through different mechanisms by  
529 each intervention. For example, the tightening pattern in acetyl-CoA synthesis, which is essentially  
530 connected to fatty acid  $\beta$ -oxidation, was similar between 17aE2 and Rapa, but different from ACA  
531 (Supplementary Fig. 1b); 17aE2 and Rapa, but not ACA, similarly modulated expression patterns of  
532 mitochondrial proteins (Fig. 3b); the longevity interventions other than MR, GHRKO, and  
533 SnellDW did not show the (significant) flux changes in fatty acid  $\beta$ -oxidation (Fig. 4d). Hence, we  
534 hypothesize that different longevity interventions lead to a similar rerouting of energy metabolism  
535 through fatty acid metabolism, albeit through different mechanisms. Although the findings from  
536 DIRAC, WGCNA and GEM do not indicate the functional direction for cells (e.g., tight regulation can  
537 be either augmentation or attenuation of a pathway), there are multiple reports about fatty acid  
538 oxidation in aging and longevity; AMPK, an essential kinase of the nutrient-sensing signaling  
539 pathways in longevity, inhibits fatty acid synthesis and promotes fatty acid oxidation via inhibition of  
540 acetyl-CoA carboxylase 1 (ACC1) and ACC2<sup>6,61</sup>; CR increases fatty acid synthesis in adipose tissue  
541 but results in enhancing whole-body oxidation<sup>62</sup>; ketogenic diet specifically upregulates the genes  
542 involved in fatty acid oxidation in liver<sup>15</sup>; overexpression of fatty acid-binding protein (FABP) or  
543 dodecenoyl-CoA delta-isomerase (DCI), corresponding to the acceleration of fatty acid  $\beta$ -oxidation,  
544 increased lifespan in *D. melanogaster*<sup>63</sup>. Therefore, tight regulation promoting fatty acid  $\beta$ -oxidation  
545 could be a common signature among longevity strategies. On the other hand, the prominence of the  
546 nutrient-sensing or energy-producing process from liver-derived datasets might be unsurprising  
547 because the liver is a major metabolic organ. However, we also observed that longevity  
548 interventions tightened the modules less often associated with liver and metabolism, such as *RIG-I*  
549 *signaling* (GO:0039529; Supplementary Fig. 1e, f, 3f) and *CD40 signaling* (GO:0023035;  
550 Supplementary Data 1). In the mid-life human female brain, metabolic and immune systems are  
551 shifted by chronological age: glucose metabolism and fatty acid  $\beta$ -oxidation are attenuated and  
552 enhanced, respectively, and chronic low-grade innate and adaptive immune responses are enhanced<sup>64</sup>.  
553 Hence, the interrelationship between fatty acid metabolism and innate/adaptive inflammation is an  
554 interesting area for future investigations.

555 Aging accompanies progressive loss of homeostasis. This intuition can be qualitatively  
556 assessed by “allosteric load” (also known as “physiological dysregulation”), and this measure  
557 increases with chronological age<sup>65-67</sup>. Hence, we anticipated that the tightness of module regulation  
558 would monotonically decrease with chronological age. However, we observed the “U-shaped”  
559 trajectory of the RCI median: the tight module regulation decreased as a function of chronological age  
560 up to mid-life, and increased from mid-life onwards (Fig. 6a, Supplementary Fig. 5c). Our consecutive  
561 analyses (Fig. 6b, f, Supplementary Fig. 5d, 6c) implied that the tight patterns of module regulation

562 were representatively characterized by a young healthy state (Y-subQ1) and an old unhealthy state (O-  
563 subQ5). Namely, one of the interpretations is that the U-shaped trajectory was deduced from the  
564 higher variations in health state among middle-aged individuals. These findings suggest that the  
565 binary interpretation of “dysregulation” is insufficient for understanding molecular and physiological  
566 processes in aging. As a limitation, we cannot deny potential effects of survivorship bias on the state  
567 transition observed in older ages, which may have diminished the monotonic reduction pattern. A  
568 further limitation is that we cannot deduce exactly which mechanisms are responsible for regulating  
569 the systems entropy that we measure (i.e., rank conservation); these mechanisms are predominantly  
570 under autonomous intracellular controls such as biochemical and transcriptional regulations but could  
571 be affected by behavioral/neurological or external/environmental controls, which may have generated  
572 the “U-shaped” pattern. Nevertheless, we have previously reported that healthy individuals have an  
573 increasingly divergent gut microbiome compositional state with age<sup>68</sup>. A bacterial microbiome in *D.*  
574 *melanogaster* is necessary for age-dependent changing patterns in metabolism and immune  
575 response<sup>69</sup>. Hence, there may be a critical link between the aging patterns of module regulation and  
576 gut microbiome, especially in metabolomic space<sup>70</sup>, which lead to the tight module regulation in older  
577 ages.

578 There are several limitations to this study. In DIRAC and GEM analyses, we pooled female  
579 and male samples due to a small sample size. Hence, it is highly possible that we failed to identify  
580 sex-dependent changes, especially related to the known sex-dependent effects of ACA, 17aE2, and  
581 Protandim on lifespan extension<sup>19-21</sup>. Because this study successfully validated the utility of systems-  
582 level approaches and because sex dimorphism in aging and longevity remains not fully elucidated<sup>71</sup>,  
583 we plan to address this point as a continued study by leveraging the upcoming datasets that are  
584 generated from experiments with larger sample sizes. Additionally, there were marked differences in  
585 study design between the mouse and human datasets (Fig. 1); the former addressed the systems that  
586 were changed by prolongevity interventions under young adults, while the latter addressed the systems  
587 that were observed across age in an adult population. To directly link the findings from mice to  
588 humans, one could theoretically compare the DIRAC metrics between short-lived and long-lived  
589 individuals or between the individuals with or without prolongevity intervention across decades, for  
590 example, although this is not so easy in practice. In addition, the regulation for biological systems may  
591 not be conserved between mouse liver and human blood. Moreover, there were few commonly  
592 examined modules between mouse liver proteomics and human blood proteomics due to the difference  
593 in the measured proteins (Supplementary Data 1, 8). Hence, our findings in mice and humans may be  
594 entirely unrelated. However, a coherent explanation may be possible to connect our mouse and human  
595 findings. Given that the median lifespans of UM-HET3 mice in our experimental facility are  
596 approximately 886 and 863 days for females and males, respectively, the mice used in this study (12  
597 months old) completed around 42% of their potential lifespan. Assuming 80 years as a median  
598 lifespan for humans, this would correspond to roughly 34 years-old humans. Therefore, the module  
599 state tightened by the prolongevity interventions in mice (Fig. 2, 3, and 5) may be related to the young  
600 healthier state observed in humans (Y-subQ1 in Fig. 6 and Supplementary Fig. 6), in line with the  
601 clinical anticipation that appropriate interventions (e.g., prolongevity drug administration, dietary CR)  
602 can slow aging in humans, at least, at young or middle stage. Further investigations, including how  
603 prolongevity interventions affect older mice, are required to deepen our understanding of systems-  
604 level regulation.  
605

## 606 **Methods**

### 607 **Mouse liver proteomic datasets**

608 Liver samples from mice fed with lifespan-extending drugs were collected as previously described<sup>57</sup>.  
609 Briefly, 12 (6 female and 6 male) genetically heterogeneous UM-HET3 mice were prepared for each  
610 sample group: control, acarbose (ACA), 17 $\alpha$ -estradiol (17aE2), and rapamycin (Rapa). The drugs  
611 were treated via daily feeding of the Purina 5LG6 diet with ACA (1,000 mg kg<sup>-1</sup>), 17aE2 (14.4 mg  
612 kg<sup>-1</sup>), or Rapa (14 mg kg<sup>-1</sup>) starting at 4 months. At 12 months, the mice fasted for 18 h and were  
613 euthanized for liver sampling. Excised livers were washed in phosphate-buffered saline (PBS) and  
614 snap-frozen for proteomic analysis. All procedures followed the methods recommended by the  
615 National Institute on Aging (NIA) Interventions Testing Program (ITP)<sup>18</sup>. Hereinafter, this experiment  
616 is called “LC-M001”.

617 Liver samples from 4EGI-1-treated mice were collected as previously described<sup>56</sup>. Each  
618 group, control and 4EGI-1, consisted of 4 female and 4 male UM-HET3 mice aged 6 to 8 months old.  
619 Controls received an intraperitoneal injection of 15  $\mu$ L dimethyl sulfoxide (DMSO) daily for 5 days,  
620 and treated mice received DMSO containing 4EGI-1 at 75 mg per kg body weight. After the last  
621 injection, the mice were fasted for 18 h prior to euthanasia. Excised livers were washed in PBS and  
622 snap-frozen for proteomic analysis. Hereinafter, this experiment is called “LC-M004”.

623 The frozen livers were dissected, processed with lysis and trypsin digestion, and analyzed by  
624 mass spectrometry (MS) for quantitative protein abundance. Liver sections were placed in lysis buffer  
625 (50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl pH 8.0 and 5% sodium dodecyl sulfate (SDS))  
626 and homogenized using a Precellys<sup>®</sup> 24 tissue homogenizer (Bertin Technologies SAS, Montigny-le-  
627 Bretonneux, France). For each sample, protein concentrations were determined by a bicinchoninic  
628 acid (BCA) assay. 300  $\mu$ g of solubilized protein extract in 5% SDS was purified to remove SDS using  
629 Midi-S-Trap<sup>™</sup> sample processing technology (ProtiFi, New York, USA), and digested with trypsin at  
630 37 °C for 4 h. The extracted tryptic peptides were subjected to reverse phase liquid chromatography  
631 tandem mass spectrometry (LC-MS/MS), using an Easy-nLC 1000 (Thermo Fisher Scientific,  
632 Massachusetts, USA) with a 50 cm fused silica capillary (75  $\mu$ m inner diameter) packed with C18  
633 (ReproSil-Pur 1.9  $\mu$ m; Dr. Maisch GMBH, Ammerbuch, Germany) heated to 45 °C. The mobile phase  
634 gradient consisted of 5–35% acetonitrile and 0.1% formic acid over 3 h for the LC-M001 samples or  
635 over 2 h for the LC-M004 samples. The LC-M001 samples were analyzed on a Q Exactive-HF mass  
636 spectrometer (Thermo Fisher Scientific) in data-dependent acquisition (DDA) mode with an MS scan  
637 mass range of 375–1375  $m/z$  and a resolution of 60,000. MS/MS scans were acquired with TopN = 15  
638 using 15,000 resolution, with an isolation width of 1.8  $m/z$ , AGC set to 100,000, and 100 ms injection  
639 time. NCE was set to 27, and dynamic exclusion was set to 20 s. The LC-M004 samples were  
640 analyzed on an Orbitrap Fusion Lumos (Thermo Fisher Scientific) in DDA mode with an MS scan  
641 mass range of 375–1375  $m/z$  and a resolution of 60,000. MS/MS scans were acquired with TopN = 12  
642 using 15,000 resolution with an isolation width of 1.8  $m/z$ , AGC set to 40,000, and 30 ms injection  
643 time. NCE was set to 30, and a dynamic exclusion was set to 30 s.

644 MS data analysis was conducted using the Trans-Proteomic Pipeline<sup>72</sup>. Peptide identification  
645 was performed by database searching with Comet<sup>73</sup> using the mouse reference proteome  
646 UP000000589 (UniProt, downloaded on June 11, 2019) filtered to one protein sequence per gene.  
647 Peptide sequences were validated with PeptideProphet<sup>74</sup> and iProphet<sup>75</sup>. Protein inference was  
648 performed with ProteinProphet<sup>76</sup>. Protein quantification was performed using the top-3 method<sup>77,78</sup> on  
649 quantities obtained from the extracted ion chromatograms of the precursor signals of the identified  
650 proteotypic peptides.  
651

### 652 **Mouse liver transcriptomic dataset**

653 The processed dataset of mouse liver transcriptomics was kindly provided by Vadim N. Gladyshev  
654 (Harvard Medical School). Complete descriptions are found in the original paper<sup>45</sup>. Briefly, the  
655 original experiment was designed to investigate eight longevity interventions: two genetically

656 modified models (the growth hormone receptor knockout mouse (GHRKO) and the hypopituitary  
657 Snell dwarf mouse (SnellDW)), two nutritional interventions (calorie restriction (CR) and methionine  
658 restriction (MR)), and four pharmacological interventions (ACA, 17aE2, Protandim<sup>®</sup>, and Rapa).  
659 Three 5 months-old male mice were prepared for each sample group in genetically modified models:  
660 SnellDW control (SnellWT), SnellDW, GHRKO control (GHRWT), and GHRKO. Three UM-HET3  
661 mice were prepared for each of the 22 sex- and age-distinguished sample groups in nutritional and  
662 pharmacological interventions: 6 months-old female of control, CR, ACA, 17aE2, Protandim, and  
663 Rapa; 12 months-old female of control, CR, ACA, and Rapa; 6 months-old male of control, CR, ACA,  
664 17aE2, Protandim, and Rapa; 12 months-old male of control, CR, ACA, and Rapa; 14 months-old  
665 male of MR control and MR. The nutritional and pharmacological interventions were treated via daily  
666 feeding of the Purina 5LG6 diet with CR (40% less than control) starting at 4 months, with MR  
667 (0.12% w/w methionine; cf. 0.86% w/w methionine in MR control) starting at 2 months, or with ACA  
668 (1,000 mg kg<sup>-1</sup>), 17aE2 (14.4 mg kg<sup>-1</sup>), Protandim (1,200 mg kg<sup>-1</sup>), or Rapa (42 or 14 mg kg<sup>-1</sup> for 6  
669 or 12 months-old, respectively) starting at 4 months. The liver samples were processed for paired-end  
670 RNA sequencing using NovaSeq 6000 sequencing system (Illumina, California, USA). The processed  
671 reads after the quality filtering and adapter removal were mapped to gene and counted. After filtering  
672 out genes with low number of reads, the count data of the filtered genes was passed to the relative log  
673 expression (RLE) normalization.  
674

### 675 **Human plasma proteomic and metabolomic datasets**

676 The original human plasma proteomic and metabolomic datasets relied on a cohort consisting of over  
677 5,000 individuals who participated in the Arivale Scientific Wellness program (Arivale, Washington,  
678 USA). Complete descriptions are found in the previous papers<sup>47,48,70</sup>. Briefly, an individual was  
679 eligible for enrollment if the individual was over 18 years old, not pregnant, and a resident of any US  
680 state except New York; participants were primarily recruited from Washington, California, and  
681 Oregon. In this program, multiomic data was collected, including human genomes, longitudinal  
682 measurements of clinical lab tests, proteomics, metabolomics, gut microbiomes, and wearable devices,  
683 and health/lifestyle questionnaires. Peripheral venous blood draws for all measurements were  
684 performed by trained phlebotomists at LabCorp (Laboratory Corporation of America Holdings, North  
685 Carolina, USA) or Quest (Quest Diagnostics, New Jersey, USA) service centers. Proteomic data was  
686 generated using proximity extension assay (PEA) for plasma derived from whole blood samples with  
687 several Olink Target panels (Olink Proteomics, Uppsala, Sweden), and measurements with the  
688 Cardiovascular II, Cardiovascular III and Inflammation panels were used in the present study since the  
689 other panels were not necessarily applied to all samples. Metabolomic data was generated using ultra-  
690 high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) for plasma  
691 derived from whole blood samples by Metabolon (North Carolina, USA). This study was conducted  
692 with deidentified data of the participants who had consented to the use of their anonymized data in  
693 research. All procedures were approved by the Western Institutional Review Board (WIRB) with  
694 Institutional Review Board (IRB) (Study Number: 20170658 at Institute for Systems Biology and  
695 1178906 at Arivale).

696 In this study, we selected the participants for whom the multiomic biological age<sup>48</sup> and  
697 general covariates (Body Mass Index (BMI) and ancestry principal components (PCs)) had been  
698 calculated, and retrieved the baseline proteomic or metabolomic dataset (i.e., the first time point  
699 measurement for each participant). Analytes which were missing in more than 10% of participants  
700 were removed, and participants who had missing values for more than 10% of the remaining analytes  
701 were removed. Missing values were imputed with random forest using Python missingpy library  
702 (version 0.2.0). Some proteins were measured on multiple Olink panels; these values were averaged to  
703 produce one value per protein. The final preprocessed proteomic and metabolomic datasets were 263  
704 proteins × 2,714 participants and 739 metabolites × 1,899 participants, respectively.  
705

### 706 **Weighted Gene Coexpression Network Analysis**

707 Weighted Gene Coexpression Network Analysis (WGCNA) was performed using R WGCNA  
708 package (version 1.69) according to the WGCNA methodology<sup>42</sup>. Analytes were initially filtered based  
709 on missing values with the default threshold setting (50%), and the remained analytes were used to  
710 generate the coexpression network. Network generation was performed using Spearman’s correlation  
711 and the signed-hybrid approach within the WGCNA package. The  $\beta$  parameter to approximate a scale-  
712 free topology was defined with 7 for the LC-M001 proteomics and 11 for the Arivale metabolomics,  
713 using the pickSoftThreshold function. Module identification was subsequently performed using the  
714 topological overlap matrix and the default hierarchical clustering approach with dynamic tree cut.  
715 Consequently, nine modules were identified for the LC-M001 proteomics (Fig. 3a) and the Arivale  
716 metabolomics (Supplementary Fig. 5b). The identified modules were summarized with “module  
717 eigengene”: the  $q$ -module eigengene  $E^{(q)}$  corresponds to the first PC of the expression matrix of  
718 proteins in that module. In addition, intramodular connectivity (i.e., the sum of the adjacency to the  
719 other nodes within the module) was calculated for each protein of the modules.  
720

## 721 **Differential Rank Conservation analysis**

### 722 – *Preprocessing*

723 To apply Differential Rank Conservation (DIRAC) analysis, missingness in the mouse datasets was  
724 conservatively resolved by filtering out the analytes that were not detected in one or more samples; the  
725 final number of analytes was 2,231 proteins for DIRAC analysis of the LC-M001 proteomics, 2,112  
726 proteins for DIRAC analysis of the LC-M001 and LC-M004 proteomics, and 11,192 transcripts for  
727 DIRAC analysis of the M001-related transcriptomics. Missingness in the human datasets was resolved  
728 by imputation during the aforementioned cohort-defining pipeline. In this study, the analyte values  
729 were normalized using “robust Z-score” (i.e., Z-score using median and median absolute deviation  
730 (MAD) instead of mean and SD, respectively) for each sample, and further normalized using robust Z-  
731 score for each analyte based on the median and MAD of the control group (mouse datasets) or the  
732 whole population (human datasets). In mouse datasets, samples with different conditions in sex and  
733 age but the same intervention were handled as a single sample group to calculate robust DIRAC rank  
734 consensus from small sample size, while recognizing the false negative risks for potential sex or age-  
735 dependent changes.

### 736 – *Module set preparation*

737 For each protein in the preprocessed datasets, the Gene Ontology Biological Process (GOBP)  
738 annotations were retrieved using the European Molecular Biology Laboratory’s European  
739 Bioinformatics Institute (EMBL-EBI) QuickGO application programming interface (API) with a  
740 query of UniProt ID (January 26, 2021 for mouse datasets; June 1, 2022 for human dataset). For each  
741 gene in the preprocessed dataset, the GOBP annotations were retrieved using R `org.Mm.eg.db`  
742 package (version 3.12.0) with a query of the Ensembl ID. Each GOBP term defines a priori module  
743 consisting of all annotated proteins/genes in the corresponding species (i.e., backgrounds). To  
744 maintain the biological meaning of annotation, the modules were further selected if at least half of the  
745 members in the module, with a minimum of four members, were quantified in the preprocessed  
746 datasets; the final a priori module set was 164 modules for DIRAC analysis of the LC-M001  
747 proteomics (Supplementary Data 1), 153 modules for DIRAC analysis of the LC-M001 and LC-M004  
748 proteomics (Supplementary Data 7), and 3,747 modules for DIRAC analysis of the M001-related  
749 transcriptomics (Supplementary Data 5). Due to the small number of quantified proteins in the  
750 preprocessed Arivale proteomics, the selection criterion was relaxed to 30% of the proteins in each  
751 module but still at least four proteins; the final a priori module set was 19 modules for DIRAC  
752 analysis of the Arivale proteomics (Supplementary Data 8).

753 Data-driven modules were prepared by applying WGCNA to each of the LC-M001  
754 proteomics and the Arivale metabolomics, as described above. Because missingness was differently  
755 handled between DIRAC analysis and WGCNA, each WGCNA-identified module could have the  
756 analytes that were not retained in the preprocessed datasets for DIRAC analysis (Fig. 3a,

757 Supplementary Fig. 5b). Hence, the WGCNA modules were further selected if at least half of the  
758 members in the module, with a minimum of four members, were retained in the preprocessed datasets;  
759 the final data-driven module set was seven modules for DIRAC analysis of the LC-M001 proteomics  
760 (Supplementary Data 2) and nine modules for DIRAC analysis of the Arivale metabolomics  
761 (Supplementary Data 9).

#### 762 – **DIRAC calculation**

763 The DIRAC algorithm<sup>40</sup> was reimplemented in Python (version 3.7.6 or 3.9.7). Briefly, pairwise  
764 comparisons of analyte values within a module are initially performed for each sample, generating a  
765 “ranking/ordering dataframe” which contains binary values about whether analyte<sub>*i*</sub> value is larger than  
766 analyte<sub>*j*</sub> value. Next, consensus of the binary values is calculated per analyte<sub>*i*</sub>–analyte<sub>*j*</sub> pair for each  
767 sample group (called “phenotype” in the original paper) by majority vote, generating a binary  
768 “ranking/ordering template dataframe” which corresponds to the “rank” consensus in the DIRAC  
769 algorithm. Then, each analyte<sub>*i*</sub>–analyte<sub>*j*</sub> pair in the ranking/ordering dataframe is judged whether it  
770 matches or mismatches with a consensus in the ranking/ordering template dataframe. Rank matching  
771 score (RMS) for each module against each consensus is obtained per sample by calculating a ratio of  
772 the number of matched pairs. Finally, RMSs for each module against each consensus is summarized  
773 with the arithmetic mean per sample group. When the mean of RMSs in a sample group is based on  
774 the consensus of the sample group itself, it corresponds to rank conservation index (RCI); that is, RCI  
775 is a special case of the RMS mean.  
776

#### 777 **Genome-scale metabolic model reconstruction**

778 For each of the samples in the M001-related transcriptomics, a “context-specific” (i.e., sample-  
779 specific) metabolic network model was reconstructed from a mouse genome-scale metabolic model  
780 (GEM), iMM1865<sup>43</sup>, which is a knowledge-based multi-compartment model consisting of 1,865  
781 metabolic genes, 10,612 reactions, and 5,839 metabolites. According to the gene–protein–reaction  
782 (GPR) associations, the RLE values were integrated with the generic iMM1865 for each sample using  
783 the integrative metabolic analysis tool (iMAT) algorithm<sup>79</sup>. Subsequently, to predict the flux values of  
784 reactions at steady state, flux variability analysis (FVA) was performed for each context-specific  
785 GEM using the COBRA toolbox (version 3.0)<sup>80</sup>. FVA evaluates the flux range for each reaction by  
786 optimizing all the potential flux distributions to minimize or maximize a pre-defined objective  
787 function under the solution space (i.e., under the context-specific constraints), which is known as the  
788 LP (Linear Programming) and MILP (Mixed Integer Linear Programming) problems. In this study, the  
789 biomass reaction (BIOMASS\_reaction) defined in the generic iMM1865 was used as the objective  
790 function to be maximized, and FVA was performed for 90% of the optimal solution using the fastFVA  
791 function. COBRA toolbox was implemented in MATLAB (R2019a), and academic licenses of Gurobi  
792 optimizer (version 7.5) and IBM CPLEX (version 12.7.1) were used to solve LP and MILP. As a  
793 result, the flux ranges were successfully predicted for 7,930 reactions among the 10,612 reactions  
794 defined in the generic GEM, and the maximum value was representatively used as the predicted flux  
795 value in this study (Supplementary Data 3).  
796

#### 797 **Statistical analysis**

798 Almost all processing and null hypothesis testing were performed using R (version 4.1.1) with R  
799 tidyverse (version 1.3.1), multcomp (version 1.4.19), dunn.test (version 1.3.5), and clusterProfiler  
800 (version 4.2.2)<sup>81</sup> packages, while correlation tests, ordinary least squares (OLS) regression analyses,  
801 and preprocessing for them were performed using Python (version 3.7.6 or 3.9.7) with Python NumPy  
802 (version 1.18.5 or 1.21.3), pandas (version 1.0.5 or 1.3.4), SciPy (version 1.4.1 or 1.7.1) and  
803 statsmodels (version 0.11.1 or 0.13.0) libraries.  $P < 0.05$  was considered statistically significant in all  
804 analyses. Group statistics (e.g., sample size, mean, SEM) and test summary (e.g., test statistic, exact  
805  $P$ -value) are found in Supplementary Data 1–9.



806 For comparing overall RCI distributions, differences in the mean of RCIs between control and  
807 each intervention were assessed using two-sided Dunnett's test (Fig. 2a, 3f, 5a) or repeated two-sided  
808 Student's *t*-tests with the multiple hypothesis adjustment by the Holm–Bonferroni method (Fig. 5e).  
809 For identifying the module changed by any of the interventions, the intervention effect on RCI (i.e.,  
810 the mean of RMSs under the rank consensus of own sample group) was assessed using Analysis of  
811 Variance (ANOVA; RMS ~ intervention) for each module (Fig. 2b, 2c, 3g, Supplementary Fig. 3a,  
812 3b) or each module and each omics (Fig. 5b), while adjusting multiple hypotheses with the  
813 Benjamini–Hochberg method. Note that GOBP modules are partly dependent on each other because  
814 the same gene/protein can be shared between GOBP terms; hence, this simple adjustment approach  
815 could inflate false negatives, and is regarded as a conservative approach. Additionally note that sex  
816 was not included in the ANOVA models since RMS and RCI themselves were calculated from the  
817 rank consensus of pooled groups, as described above. For subsequently clarifying which intervention  
818 changed (tightened or loosened) the module, the post hoc comparisons for RCI between control and  
819 each intervention were assessed using two-sided Dunnett's test (Fig. 2b–d, 3g, 3h, 5h, Supplementary  
820 Fig. 1a, 1c, 1e, 3a–c, 3g, 3j) or repeated two-sided Student's *t*-tests with the multiple hypothesis  
821 adjustment by the Holm–Bonferroni method (Fig. 5b–d). For examining the similarity of module  
822 regulation among interventions (Fig. 2c, 2e, 3i, Supplementary Fig. 1b, 1d, 1f, 3b, 3d), differences in  
823 the mean of RMSs between control and each intervention were assessed for each rank consensus using  
824 two-sided Dunnett's test. Note that the sample group corresponding to the rank consensus group was  
825 excluded from these tests, because its mean of RMSs (i.e., RCI) is expected to follow different  
826 distribution from the other sample groups' one. For identifying the module whose regulation similarity  
827 to the LC-M004 sample groups (Control-2, 4EGI-1) was different among the LC-M001 sample groups  
828 (Control-1, ACA, 17aE2, Rapa), the intervention effect on the RMS mean was assessed using  
829 ANOVA (RMS ~ intervention) for each module and each rank consensus, while adjusting multiple  
830 hypotheses with the Benjamini–Hochberg method (i.e., a conservative approach, as described above).  
831 For subsequently clarifying which intervention (similarly or dissimilarly) changed the module (Fig. 5f,  
832 5g, Supplementary Fig. 3e, 3f, 3h, 3i), the post hoc comparisons for the RMS mean between Control-1  
833 and each intervention (ACA, 17aE2, Rapa) were assessed using repeated two-sided Student's *t*-tests  
834 with the multiple hypothesis adjustment by the Holm–Bonferroni method. For examining whether the  
835 RCI median was dependent on the characteristics of each group (Supplementary Fig. 4b), two-sided  
836 statistical significance of the RCI median was assessed using a permutation test where an empirical  
837 null-hypothesis distribution of the RCI median was estimated from 20,000 DIRAC re-calculations  
838 with the shuffles of sample–group correspondence, while adjusting multiple hypotheses with the  
839 Holm–Bonferroni method. For examining overall relationship between the similarity of module  
840 regulation and stratified group, Spearman's correlation between the mean of RMSs and the quantile  
841 order of stratified groups was assessed for each sex and each rank consensus (Fig. 6b, Supplementary  
842 Fig. 5d) or each sex, each chronological age tertile (CA3) group, and each rank consensus (Fig. 6f,  
843 Supplementary Fig. 6c), while adjusting multiple hypotheses with the Holm–Bonferroni method. For  
844 identifying the module whose regulation similarity was associated with chronological age (Fig. 6c, 6d,  
845 Supplementary Fig. 5e, 5f), RMS was regressed to chronological age with BMI and ancestry PC1–5 as  
846 covariates (RMS ~ chronological age + log(BMI) + PC1 + PC2 + PC3 + PC4 + PC5) for each module,  
847 each sex, and each rank consensus, while adjusting multiple hypotheses with the Benjamini–Hochberg  
848 method (i.e., a conservative approach for GOBP modules, as described above). For identifying the  
849 module whose regulation similarity was associated with  $\Delta$  age (Fig. 6g, Supplementary Fig. 4d, 6d,  
850 6e), RMS was regressed to  $\Delta$  age with chronological age, BMI, and ancestry PC1–5 as covariates  
851 (RMS ~  $\Delta$  age + chronological age + log(BMI) + PC1 + PC2 + PC3 + PC4 + PC5) for each module,  
852 each sex, each CA3 group, and each rank consensus, while adjusting multiple hypotheses with the  
853 Benjamini–Hochberg method (i.e., a conservative approach for GOBP modules, as described above).

854 For identifying the WGCNA module changed by any of the interventions, the intervention  
855 effect on the module eigengene was assessed using ANOVA ( $E^{(g)} \sim$  intervention + sex + intervention  
856  $\times$  sex) for each module, while adjusting multiple hypotheses with the Bonferroni method. For  
857 subsequently clarifying which intervention changed the module eigengene (Fig. 3b), the post hoc  
858 comparisons for the  $E^{(g)}$  mean between control and each intervention were assessed using two-sided

859 Dunnett's test. For examining the relationship between the intervention effect on each protein in the  
860 module and their respective intramodular connectivity (Fig. 3d), the main effect of intervention on  
861 each protein  $k$  was calculated using ANOVA ( $\text{Protein}_k^{(g)} \sim \text{intervention} + \text{sex} + \text{intervention} \times \text{sex}$ ),  
862 and then Spearman's correlation between the calculated main effect of intervention and intramodular  
863 connectivity was assessed.

864 For identifying the reaction whose flux was changed by any of the interventions (Fig. 4a), the  
865 intervention effect on the flux value was assessed using Kruskal–Wallis  $H$ -test (flux value  $\sim$   
866 intervention) for each reaction, while adjusting multiple hypotheses with the Benjamini–Hochberg  
867 method. Note that reactions in GEM are partly dependent on each other because the same  
868 gene/protein/metabolite can be shared between the reactions; hence, this simple adjustment approach  
869 could inflate false negatives, and is regarded as a conservative approach. Additionally note that  
870 samples were pooled per intervention to increase the statistical power from small sample size, while  
871 recognizing the false negative risks for potential sex or age-dependent changes. For subsequently  
872 clarifying which intervention changed the reaction flux (Fig. 4b–d), the post hoc comparisons for the  
873 flux value median between control and each intervention were assessed using two-sided Dunn's test  
874 with the multiple hypothesis adjustment by the Holm–Bonferroni method. For examining the  
875 difference between CR and MR (Supplementary Fig. 2c–f), the additional post hoc comparisons were  
876 assessed between CR and its control, between MR and its control, and between CR and MR. For  
877 examining which subsystems in GEM were shifted by ACA, MR, GHRKO, and SnellDW (Fig. 4e,  
878 Supplementary Fig. 2a, 2b) or differently shifted between CR and MR (Supplementary Fig. 2g),  
879 enrichment in the significantly changed reactions was assessed using overrepresentation test for each  
880 of the subsystems that were annotated to any of the significantly changed reactions, while adjusting  
881 multiple hypotheses with the Benjamini–Hochberg method.  
882

## 883 **Data visualization**

884 Almost all results were visualized using Python (version 3.7.6 or 3.9.7) with Python matplotlib  
885 (version 3.1.3 or 3.4.3), seaborn (version 0.10.1 or 0.11.2), venn (version 0.1.3) libraries, while the  
886 results of enrichment analyses were visualized using R (version 4.1.1) with R ggplot2 (version 3.3.6)  
887 and enrichplot (version 1.14.2) packages. The results were summarized as the mean with 95%  
888 confidence interval (CI) or the boxplot, as indicated in each figure legend. Note that this 95% CI of  
889 mean or median was simultaneously calculated during visualization using the seaborn barplot or  
890 boxplot API, respectively; hence, this CI is not exactly same with that used in statistical analysis but  
891 for presentation purpose only. Hierarchical clustering was simultaneously performed during  
892 visualization using seaborn clustermap API with the Ward's linkage method for Euclidean distance.  
893 For the values used in Fig. 4a, the group mean of flux values for each reaction was centered by  
894 subtracting the group mean of the corresponding control, and then scaled by the maximum absolute  
895 value across intervention groups using MaxAbsScaler of Python scikit-learn library (version 1.0.1). In  
896 the scatterplots with regression lines, the adjusted sample RMS with the covariates was calculated as  
897 the mean  $\pm$  residual using the OLS linear regression for each plot that was the same used in statistical  
898 analysis except for dropping the independent variable (i.e., chronological age in Fig. 6d,  
899 Supplementary Fig. 5f;  $\Delta$  age in Supplementary Fig. 4d, 6e), and the regression line with 95% CI was  
900 simultaneously computed during visualization using the seaborn regplot API.  
901

## 902 **Data availability**

903 The MS data of the LC-M001 and LC-M004 proteomics have been deposited to the ProteomeXchange  
904 Consortium via the PRIDE partner repository (PXD035255)<sup>82</sup>. Note that this data will be available  
905 after journal publication; until then, requests should be directed to the corresponding authors. The  
906 processed data of M001-related transcriptomics was kindly provided by Vadim N. Gladyshev  
907 (Harvard Medical School), and raw data is available on the NCBI's Gene Expression Omnibus (GEO)  
908 repository (GSE131901). The Arivale datasets can be accessed by qualified researchers for research

909 purposes. Requests should be sent to [data-access@isbscience.org](mailto:data-access@isbscience.org). The de-identified data will be  
910 available to the qualified researchers on submission and approval of a research plan.  
911

912 **Code availability**

913 Code used in this study is freely available in GitHub (<https://github.com/longevity-consortium>).  
914

## 915 References

- 916 1. Kennedy, B. K. *et al.* Geroscience: linking aging to chronic disease. *Cell* **159**, 709–13 (2014).  
917 2. Kubben, N. & Misteli, T. Shared molecular and cellular mechanisms of premature ageing and ageing-  
918 associated diseases. *Nat. Rev. Mol. Cell Biol.* **18**, 595–609 (2017).  
919 3. Kaeberlein, M., Rabinovitch, P. S. & Martin, G. M. Healthy aging: The ultimate preventative medicine.  
920 *Science* **350**, 1191–3 (2015).  
921 4. Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges of ageing. *Nature* **561**, 45–56  
922 (2018).  
923 5. Fontana, L., Partridge, L. & Longo, V. D. Extending healthy life span--from yeast to humans. *Science* **328**,  
924 321–6 (2010).  
925 6. Burkewitz, K., Zhang, Y. & Mair, W. B. AMPK at the nexus of energetics and aging. *Cell Metab.* **20**, 10–25  
926 (2014).  
927 7. Imai, S. & Guarente, L. NAD<sup>+</sup> and sirtuins in aging and disease. *Trends Cell Biol.* **24**, 464–71 (2014).  
928 8. Johnson, S. C., Rabinovitch, P. S. & Kaeberlein, M. mTOR is a key modulator of ageing and age-related  
929 disease. *Nature* **493**, 338–45 (2013).  
930 9. Kennedy, B. K. & Lamming, D. W. The Mechanistic Target of Rapamycin: The Grand ConducTOR of  
931 Metabolism and Aging. *Cell Metab.* **23**, 990–1003 (2016).  
932 10. de Cabo, R., Carmona-Gutierrez, D., Bernier, M., Hall, M. N. & Madeo, F. The search for antiaging  
933 interventions: from elixirs to fasting regimens. *Cell* **157**, 1515–26 (2014).  
934 11. Vaiserman, A. M., Lushchak, O. V. & Koliada, A. K. Anti-aging pharmacology: Promises and pitfalls.  
935 *Ageing Res. Rev.* **31**, 9–35 (2016).  
936 12. Partridge, L., Fuentealba, M. & Kennedy, B. K. The quest to slow ageing through drug discovery. *Nat. Rev.*  
937 *Drug Discov.* **19**, 513–532 (2020).  
938 13. Masoro, E. J. Overview of caloric restriction and ageing. *Mech. Ageing Dev.* **126**, 913–22 (2005).  
939 14. Parkhitko, A. A., Jouandin, P., Mohr, S. E. & Perrimon, N. Methionine metabolism and methyltransferases  
940 in the regulation of aging and lifespan extension across species. *Ageing Cell* **18**, e13034 (2019).  
941 15. Newman, J. C. *et al.* Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice. *Cell*  
942 *Metab.* **26**, 547–557.e8 (2017).  
943 16. Roberts, M. N. *et al.* A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice. *Cell Metab.* **26**,  
944 539–546.e5 (2017).  
945 17. Moskalev, A. *et al.* Geroprotectors.org: a new, structured and curated database of current therapeutic  
946 interventions in aging and age-related disease. *Ageing (Albany, NY)*. **7**, 616–28 (2015).  
947 18. Nadon, N. L. *et al.* Design of aging intervention studies: the NIA interventions testing program. *Age*  
948 *(Dordr)*. **30**, 187–99 (2008).  
949 19. Harrison, D. E. *et al.* Acarbose, 17- $\alpha$ -estradiol, and nordihydroguaiaretic acid extend mouse lifespan  
950 preferentially in males. *Ageing Cell* **13**, 273–82 (2014).  
951 20. Strong, R. *et al.* Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an  $\alpha$ -  
952 glucosidase inhibitor or a Nrf2-inducer. *Ageing Cell* **15**, 872–84 (2016).  
953 21. Harrison, D. E. *et al.* Acarbose improves health and lifespan in aging HET3 mice. *Ageing Cell* **18**, e12898  
954 (2019).  
955 22. Miller, R. A. *et al.* Canagliflozin extends life span in genetically heterogeneous male but not female mice.  
956 *JCI insight* **5**, (2020).  
957 23. Harrison, D. E. *et al.* 17- $\alpha$ -estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide  
958 riboside and three other drugs do not affect lifespan in either sex. *Ageing Cell* **20**, e13328 (2021).  
959 24. Miller, R. A. *et al.* Glycine supplementation extends lifespan of male and female mice. *Ageing Cell* **18**,  
960 e12953 (2019).  
961 25. Strong, R. *et al.* Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male  
962 mice. *Ageing Cell* **7**, 641–50 (2008).  
963 26. Harrison, D. E. *et al.* Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*  
964 **460**, 392–5 (2009).  
965 27. Miller, R. A. *et al.* Rapamycin, but not resveratrol or simvastatin, extends life span of genetically  
966 heterogeneous mice. *J. Gerontol. A. Biol. Sci. Med. Sci.* **66**, 191–201 (2011).  
967 28. Miller, R. A. *et al.* Rapamycin-mediated lifespan increase in mice is dose and sex dependent and  
968 metabolically distinct from dietary restriction. *Ageing Cell* **13**, 468–77 (2014).  
969 29. Weichhart, T. mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review. *Gerontology* **64**, 127–134 (2018).  
970

- 971 30. Arriola Apelo, S. I. & Lamming, D. W. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of  
972 Easter Island. *J. Gerontol. A. Biol. Sci. Med. Sci.* **71**, 841–9 (2016).
- 973 31. Lamming, D. W., Ye, L., Sabatini, D. M. & Baur, J. A. Rapalogs and mTOR inhibitors as anti-aging  
974 therapeutics. *J. Clin. Invest.* **123**, 980–9 (2013).
- 975 32. Saxton, R. A. & Sabatini, D. M. mTOR Signaling in Growth, Metabolism, and Disease. *Cell* **168**, 960–976  
976 (2017).
- 977 33. Krentz, A. J. & Bailey, C. J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. *Drugs* **65**,  
978 385–411 (2005).
- 979 34. Herrera, J. J. *et al.* Acarbose has sex-dependent and -independent effects on age-related physical function,  
980 cardiac health, and lipid biology. *JCI insight* **5**, (2020).
- 981 35. Gibbs, V. K., Brewer, R. A., Miyasaki, N. D., Patki, A. & Smith, D. L. Sex-dependent Differences in Liver  
982 and Gut Metabolomic Profiles With Acarbose and Calorie Restriction in C57BL/6 Mice. *J. Gerontol. A.*  
983 *Biol. Sci. Med. Sci.* **73**, 157–165 (2018).
- 984 36. Dykens, J. A., Moos, W. H. & Howell, N. Development of 17alpha-estradiol as a neuroprotective  
985 therapeutic agent: rationale and results from a phase I clinical study. *Ann. N. Y. Acad. Sci.* **1052**, 116–35  
986 (2005).
- 987 37. Toran-Allerand, C. D. Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol. *Ann. N. Y.*  
988 *Acad. Sci.* **1052**, 136–44 (2005).
- 989 38. Debarba, L. K., Jayarathne, H. S. M., Miller, R. A., Garratt, M. & Sadagurski, M. 17- $\alpha$ -Estradiol Has Sex-  
990 Specific Effects on Neuroinflammation That Are Partly Reversed by Gonadectomy. *J. Gerontol. A. Biol. Sci.*  
991 *Med. Sci.* **77**, 66–74 (2022).
- 992 39. Garratt, M. *et al.* Male lifespan extension with 17- $\alpha$  estradiol is linked to a sex-specific metabolomic  
993 response modulated by gonadal hormones in mice. *Aging Cell* **17**, e12786 (2018).
- 994 40. Eddy, J. A., Hood, L., Price, N. D. & Geman, D. Identifying tightly regulated and variably expressed  
995 networks by Differential Rank Conservation (DIRAC). *PLoS Comput. Biol.* **6**, e1000792 (2010).
- 996 41. Zhang, B. & Horvath, S. A general framework for weighted gene co-expression network analysis. *Stat. Appl.*  
997 *Genet. Mol. Biol.* **4**, Article17 (2005).
- 998 42. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC*  
999 *Bioinformatics* **9**, 559 (2008).
- 1000 43. Khodaei, S., Asgari, Y., Totonchi, M. & Karimi-Jafari, M. H. iMM1865: A New Reconstruction of Mouse  
1001 Genome-Scale Metabolic Model. *Sci. Rep.* **10**, 6177 (2020).
- 1002 44. Seif, Y. & Palsson, B. Ø. Path to improving the life cycle and quality of genome-scale models of  
1003 metabolism. *Cell Syst.* **12**, 842–859 (2021).
- 1004 45. Tyshkovskiy, A. *et al.* Identification and Application of Gene Expression Signatures Associated with  
1005 Lifespan Extension. *Cell Metab.* **30**, 573-593.e8 (2019).
- 1006 46. Leppek, K., Das, R. & Barna, M. Functional 5' UTR mRNA structures in eukaryotic translation regulation  
1007 and how to find them. *Nat. Rev. Mol. Cell Biol.* **19**, 158–174 (2018).
- 1008 47. Price, N. D. *et al.* A wellness study of 108 individuals using personal, dense, dynamic data clouds. *Nat.*  
1009 *Biotechnol.* **35**, 747–756 (2017).
- 1010 48. Earls, J. C. *et al.* Multi-Omic Biological Age Estimation and Its Correlation With Wellness and Disease  
1011 Phenotypes: A Longitudinal Study of 3,558 Individuals. *J. Gerontol. A. Biol. Sci. Med. Sci.* **74**, S52–S60  
1012 (2019).
- 1013 49. Barabási, A.-L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human  
1014 disease. *Nat. Rev. Genet.* **12**, 56–68 (2011).
- 1015 50. Li, L. *et al.* In vivo stabilization of OPA1 in hepatocytes potentiates mitochondrial respiration and  
1016 gluconeogenesis in a prohibitin-dependent way. *J. Biol. Chem.* **294**, 12581–12598 (2019).
- 1017 51. Jian, C. *et al.* Deficiency of PHB complex impairs respiratory supercomplex formation and activates  
1018 mitochondrial flashes. *J. Cell Sci.* **130**, 2620–2630 (2017).
- 1019 52. Artal-Sanz, M. & Tavernarakis, N. Prohibitin couples diapause signalling to mitochondrial metabolism  
1020 during ageing in *C. elegans*. *Nature* **461**, 793–7 (2009).
- 1021 53. Bordbar, A., Monk, J. M., King, Z. A. & Palsson, B. O. Constraint-based models predict metabolic and  
1022 associated cellular functions. *Nat. Rev. Genet.* **15**, 107–20 (2014).
- 1023 54. Gu, C., Kim, G. B., Kim, W. J., Kim, H. U. & Lee, S. Y. Current status and applications of genome-scale  
1024 metabolic models. *Genome Biol.* **20**, 121 (2019).
- 1025 55. López-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**,  
1026 1194–217 (2013).

- 1027 56. Ozkurede, U. *et al.* Cap-independent mRNA translation is upregulated in long-lived endocrine mutant mice. *J. Mol. Endocrinol.* **63**, 123–138 (2019).
- 1028
- 1029 57. Shen, Z., Hinson, A., Miller, R. A. & Garcia, G. G. Cap-independent translation: A shared mechanism for
- 1030 lifespan extension by rapamycin, acarbose, and 17 $\alpha$ -estradiol. *Aging Cell* **20**, e13345 (2021).
- 1031 58. Moerke, N. J. *et al.* Small-molecule inhibition of the interaction between the translation initiation factors
- 1032 eIF4E and eIF4G. *Cell* **128**, 257–67 (2007).
- 1033 59. Gorbunova, V., Seluanov, A., Zhang, Z., Gladyshev, V. N. & Vijg, J. Comparative genetics of longevity and
- 1034 cancer: Insights from long-lived rodents. *Nat. Rev. Genet.* **15**, 531–540 (2014).
- 1035 60. Reddy, J. K. & Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor
- 1036 alpha: an adaptive metabolic system. *Annu. Rev. Nutr.* **21**, 193–230 (2001).
- 1037 61. Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy
- 1038 homeostasis. *Nat. Rev. Mol. Cell Biol.* **13**, 251–62 (2012).
- 1039 62. Bruss, M. D., Khambatta, C. F., Ruby, M. A., Aggarwal, I. & Hellerstein, M. K. Calorie restriction increases
- 1040 fatty acid synthesis and whole body fat oxidation rates. *Am. J. Physiol. Endocrinol. Metab.* **298**, E108-16
- 1041 (2010).
- 1042 63. Lee, S.-H., Lee, S.-K., Paik, D. & Min, K.-J. Overexpression of fatty-acid- $\beta$ -oxidation-related genes extends
- 1043 the lifespan of *Drosophila melanogaster*. *Oxid. Med. Cell. Longev.* **2012**, 854502 (2012).
- 1044 64. Wang, Y., Mishra, A. & Brinton, R. D. Transitions in metabolic and immune systems from pre-menopause
- 1045 to post-menopause: implications for age-associated neurodegenerative diseases. *F1000Research* **9**, (2020).
- 1046 65. Crimmins, E. M., Johnston, M., Hayward, M. & Seeman, T. Age differences in allostatic load: an index of
- 1047 physiological dysregulation. *Exp. Gerontol.* **38**, 731–4 (2003).
- 1048 66. Cohen, A. A. *et al.* A novel statistical approach shows evidence for multi-system physiological
- 1049 dysregulation during aging. *Mech. Ageing Dev.* **134**, 110–7 (2013).
- 1050 67. Li, Q. *et al.* Homeostatic dysregulation proceeds in parallel in multiple physiological systems. *Aging Cell*
- 1051 **14**, 1103–12 (2015).
- 1052 68. Wilmanski, T. *et al.* Gut microbiome pattern reflects healthy ageing and predicts survival in humans. *Nat.*
- 1053 *Metab.* **3**, 274–286 (2021).
- 1054 69. Shukla, A. K., Johnson, K. & Giniger, E. Common features of aging fail to occur in *Drosophila* raised
- 1055 without a bacterial microbiome. *iScience* **24**, 102703 (2021).
- 1056 70. Wilmanski, T. *et al.* Blood metabolome predicts gut microbiome  $\alpha$ -diversity in humans. *Nat. Biotechnol.* **37**,
- 1057 1217–1228 (2019).
- 1058 71. Singh, P. P., Demmitt, B. A., Nath, R. D. & Brunet, A. The Genetics of Aging: A Vertebrate Perspective.
- 1059 *Cell* **177**, 200–220 (2019).
- 1060 72. Deutsch, E. W. *et al.* Trans-Proteomic Pipeline, a standardized data processing pipeline for large-scale
- 1061 reproducible proteomics informatics. *Proteomics. Clin. Appl.* **9**, 745–54 (2015).
- 1062 73. Eng, J. K., Jahan, T. A. & Hoopmann, M. R. Comet: an open-source MS/MS sequence database search tool.
- 1063 *Proteomics* **13**, 22–4 (2013).
- 1064 74. Keller, A., Nesvizhskii, A. I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate the
- 1065 accuracy of peptide identifications made by MS/MS and database search. *Anal. Chem.* **74**, 5383–92 (2002).
- 1066 75. Shteynberg, D. *et al.* iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide
- 1067 and protein identification rates and error estimates. *Mol. Cell. Proteomics* **10**, M111.007690 (2011).
- 1068 76. Nesvizhskii, A. I., Keller, A., Kolker, E. & Aebersold, R. A statistical model for identifying proteins by
- 1069 tandem mass spectrometry. *Anal. Chem.* **75**, 4646–58 (2003).
- 1070 77. Ludwig, C., Claassen, M., Schmidt, A. & Aebersold, R. Estimation of absolute protein quantities of
- 1071 unlabeled samples by selected reaction monitoring mass spectrometry. *Mol. Cell. Proteomics* **11**,
- 1072 M111.013987 (2012).
- 1073 78. Liu, Y. *et al.* Quantitative variability of 342 plasma proteins in a human twin population. *Mol. Syst. Biol.* **11**,
- 1074 786 (2015).
- 1075 79. Zur, H., Ruppin, E. & Shlomi, T. iMAT: an integrative metabolic analysis tool. *Bioinformatics* **26**, 3140–2
- 1076 (2010).
- 1077 80. Heirendt, L. *et al.* Creation and analysis of biochemical constraint-based models using the COBRA Toolbox
- 1078 v.3.0. *Nat. Protoc.* **14**, 639–702 (2019).
- 1079 81. Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innov. (New York,*
- 1080 *N.Y.)* **2**, 100141 (2021).
- 1081 82. Deutsch, E. W. *et al.* The ProteomeXchange consortium in 2020: Enabling ‘big data’ approaches in
- 1082 proteomics. *Nucleic Acids Res.* **48**, D1145–D1152 (2020).

1083

1084 **Acknowledgements**

1085 We thank Vadim N. Gladyshev (Harvard Medical School) for kindly providing the processed dataset  
1086 of mouse liver transcriptomics; Eric S. Orwoll (Oregon Health and Science University) and Gilbert S.  
1087 Omenn (University of Michigan) for providing comments to the manuscript; Jennifer Dougherty and  
1088 Mary Brunkow (Institute for Systems Biology) for their coordination efforts in the National Institute  
1089 on Aging (NIA) Longevity Consortium; all Arivale participants who consented to using their  
1090 deidentified data for research purposes. This work was funded by the National Institutes of Health  
1091 (NIH) grant U19AG023122 awarded by NIA (to S.R.C., N.J.S., R.A.M., R.L.M., and N.R.), the M.J.  
1092 Murdock Charitable Trust (Reference No. 2014096:MNL:11/20/2014, awarded to N.D.P. and L.H.),  
1093 and a generous gift from Carole Ellison (to K.W. and T.W.). K.W. was supported by The Uehara  
1094 Memorial Foundation (Overseas Postdoctoral Fellowships).

1096 **Author Contribution**

1097 K.W., T.W., P.B., M.R., R.A.M., R.L.M., and N.R. conceptualized the study. K.W., T.W., P.B., M.R.,  
1098 and N.R. participated in the study design. G.G.G. and R.A.M. performed mouse experiments. M.R.H.,  
1099 M.K.M., D.H.B., M.M., S.R.M., K.M.C., C.K., U.K., and R.L.M. contributed to the generation of the  
1100 mouse proteomics. J.C.L. and A.T.M. managed the logistics of data collection and integration for the  
1101 human datasets. K.W., T.W., and P.B. performed data analysis and figure generation. J.W., J.L., C.L.,  
1102 J.C.R., G.G., S.R.C., N.J.S., N.D.P., and L.H. assisted in result interpretation. K.W., T.W., P.B., M.R.,  
1103 and N.R. were the primary authors of the paper, with contributions from all other authors. All authors  
1104 read and approved the final manuscript.


1106 **Competing Interests**

1107 The authors declare no competing interests.

1108



1109 **Figures**



1110

1111

**Figure 1. Study design overview.**

1112

1113


1114

1115

1116

1117

Schematic representation of this study. Utilizing five omics datasets and three systems-level analyses, this study addresses systems-level changes in the molecular regulation of biological processes under multiple longevity interventions in mice and across age in humans. LC: Longevity Consortium, a project supported by the National Institute on Aging (NIA). Dataset 2 was generated in the previous study<sup>45</sup>. Datasets 4 and 5 were collected through the previous studies<sup>47,48</sup>.



**Figure 2. Prolongevity interventions tightened the regulation of a priori proteomic modules.**

**a–e** Differential Rank Conservation (DIRAC) analysis of the LC-M001 liver proteomics using Gene Ontology Biological Process (GOBP)-defined modules (see Supplementary Data 1 for complete results). **a, b** Overall distribution of module rank conservation index (RCI). Data (**a**): the 25<sup>th</sup> percentile ( $Q_1$ , box bottom), median (center line, notch: 95% confidence interval (CI) for the median), and the 75<sup>th</sup> percentile ( $Q_3$ , box top); whiskers span  $[\max(x_{\min}, Q_1 - 1.5 \times IQR), \min(x_{\max}, Q_3 + 1.5 \times IQR)]$ , where  $x_{\min}$  and  $x_{\max}$  are the minimum and maximum, respectively, in the observed values and  $IQR = Q_3 - Q_1$ ;  $n = 164$  modules.  $***P < 0.001$  by two-sided Dunnett’s test. Top color columns in **b** highlight the modules that exhibited nominal or “conservatively” false discovery rate (FDR)-adjusted  $P < 0.05$  (see Methods) for the main effect of intervention on each module RCI by Analysis of Variance (ANOVA) and that exhibited significantly higher RCI in intervention group than control group (i.e., “tightened” module;  $P < 0.05$  by post hoc two-sided Dunnett’s test). **c** Venn diagrams of the significantly tightened modules by each intervention (conservatively FDR-adjusted  $P < 0.05$ ). For the tightened modules in each intervention group, sub-venn diagram indicates the modules for which the other intervention groups exhibited significantly higher or lower mean of rank matching scores (RMSs) under the rank consensus than control group (i.e., “similarly” or “dissimilarly” changed module to the consensus group, respectively;  $P < 0.05$  by two-sided Dunnett’s test). n/a: logically not available. **d, e** Sample RMS distributions for an example of the tightened modules (GO:0031998, regulation of fatty acid  $\beta$ -oxidation). Dashed line in **e** indicates the mean of RMSs for the sample group corresponding to the rank consensus (i.e., RCI). Data: the mean (dot) with 95% CI (bar);  $n = 12$  mice.  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$  by two-sided Dunnett’s test.

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135


1136

1137

1138

1139


1140



**Figure 3. Prolongevity interventions tightened the regulation of data-driven proteomic modules.**

**a–e** Weighted Gene Co-expression Network Analysis (WGCNA) of the LC-M001 liver proteomics. **a** The number of proteins in each WGCNA-identified module. WGCNA: proteins used in WGCNA, DIRAC: proteins retained after the processing for Differential Rank Conservation (DIRAC) analysis (**f–i**). **b** Sample eigenvalue distributions for the Darkgreen module. Data: the 25<sup>th</sup> percentile ( $Q_1$ , box bottom), median (center line), and the 75<sup>th</sup> percentile ( $Q_3$ , box top); whiskers span  $[\max(x_{\min}, Q_1 - 1.5 \times IQR), \min(x_{\max}, Q_3 + 1.5 \times IQR)]$ , where  $x_{\min}$  and  $x_{\max}$  are the minimum and maximum, respectively, in the observed values and  $IQR = Q_3 - Q_1$ ;  $n = 12$  mice.  $*P < 0.05$ ,  $**P < 0.01$  by two-sided Dunnett's test. **c** Principal component (PC) analysis of each sample's Darkgreen-module protein levels. The percentage of the axis title indicates the explained variance by the PC. **d** Relationship between the intervention effect on each protein in the Darkgreen module and their respective intramodular connectivity. The  $P$ -value of y-axis corresponds to the main effect of intervention on each protein level by Analysis of Variance (ANOVA). Each boxplot metric is the same with **b**. **e** Top 30 hub proteins within the Darkgreen module. Green, gray, and white colors correspond to mitochondrial, cytosolic metabolism-related, and other proteins, respectively. **f–i** DIRAC analysis of the LC-M001 liver proteomics using WGCNA-identified modules (see Supplementary Data 2 for complete results). **f, g** Overall distribution of module rank conservation index (RCI). Data (**f**): each boxplot metric is the same with **b**;  $n = 7$  modules.  $***P < 0.001$  by two-sided Dunnett's test. Top color columns in **g** highlight the modules that exhibited false discovery rate (FDR)-adjusted  $P < 0.05$  for the main effect of intervention on each module RCI by ANOVA and that exhibited significantly higher RCI in intervention group than control group (i.e., "tightened" module;  $P < 0.05$  by post hoc two-sided Dunnett's test). **h, i** Sample rank matching score (RMS) distributions for the Darkgreen module. Dashed line in **i** indicates the mean of RMSs for the sample group corresponding to the rank

1165 consensus (i.e., RCI). Data: the mean (dot) with 95% CI (bar);  $n = 12$  mice.  $*P < 0.05$ ,  $**P < 0.01$ ,  
1166  $***P < 0.001$  by two-sided Dunnett's test.  
1167



**Figure 4. Prolongevity interventions shifted the flux regulation in fatty acid metabolism.**

**a–e** An integrated analysis of the M001-related liver transcriptomics<sup>45</sup> with mouse genome-scale metabolic model (GEM; see Supplementary Data 3 and 4 for complete results). CR: calorie restriction; MR: methionine restriction; GHR: growth hormone receptor; WT: wild-type; KO: knockout; Control 1: control for Acarbose, 17 $\alpha$ -Estradiol, Protandim, Rapamycin, and CR diet; Control 2: control for MR diet. **a** Change in the group mean of flux values for each reaction. The presented group mean value was centered and scaled (see Methods); i.e., its positive value corresponds to an increase in the

1168

1169

1170

1171


1172

1173

1174

1175

1176 mean of flux values compared to corresponding control group, and vice versa. Among 7,930 reactions  
1177 whose flux values were successfully predicted across all samples (78 mice), presented are the 2,156  
1178 reactions that exhibited nominal or “conservatively” false discovery rate (FDR)-adjusted  $P < 0.05$  (see  
1179 Methods) for the main effect of intervention on each flux median by Kruskal–Wallis  $H$ -test and that  
1180 exhibited significantly different flux median in intervention group from control group (i.e., “changed”  
1181 reaction;  $P < 0.05$  by post hoc two-sided Dunn’s test with the Holm–Bonferroni adjustment). These  
1182 significantly changed modules are highlighted in the top color columns per intervention group, except  
1183 for  $17\alpha$ -Estradiol, Protandim, and CR diet due to no significantly changed reactions by them. **b, c**  
1184 Venn diagrams of the significantly changed reactions by each intervention (conservatively FDR-  
1185 adjusted  $P < 0.05$ ). **d** Changed reactions within the central energy metabolism. The 25 reaction IDs  
1186 highlighted in the diagram are the reactions that had the predicted flux values across all samples. Flux  
1187 value distributions are presented for the 10 reactions that exhibited nominal  $P < 0.05$  by the  
1188 aforementioned Kruskal–Wallis  $H$ -test. Data: the 25<sup>th</sup> percentile ( $Q_1$ , box bottom), median (center  
1189 line), and the 75<sup>th</sup> percentile ( $Q_3$ , box top); whiskers span [ $\max(x_{\min}, Q_1 - 1.5 \times \text{IQR}), \min(x_{\max}, Q_3 +$   
1190  $1.5 \times \text{IQR})$ ], where  $x_{\min}$  and  $x_{\max}$  are the minimum and maximum, respectively, in the observed values  
1191 and  $\text{IQR} = Q_3 - Q_1$ ;  $n = 12$  (Control 1, Acarbose, Rapamycin, CR diet), 6 ( $17\alpha$ -Estradiol, Protandim),  
1192 3 (the others) mice. \* $P < 0.05$ , \*\* $P < 0.01$  by two-sided Dunn’s test with the Holm–Bonferroni  
1193 adjustment. **e** Shifted subsystems by MR diet. Significance of the shifted subsystems was assessed  
1194 using enrichment analysis on the significantly changed reactions (conservatively FDR-adjusted  $P <$   
1195  $0.05$ ) while adjusting multiple hypotheses with the Benjamini–Hochberg method. Only the subsystems  
1196 that exhibited nominal  $P < 0.05$  are presented. AdjPval: FDR-adjusted  $P$ -value from the enrichment  
1197 analysis.  
1198



**Figure 5. Prolongevity interventions likely tightened the module regulation partly through cap-independent translation.**

**a** Differential Rank Conservation (DIRAC) analysis of the M001-related liver transcriptomics using Gene Ontology Biological Process (GOBP)-defined modules (see Supplementary Data 5 for complete results). Presented is overall distribution of module rank conservation index (RCI). CR: calorie restriction. Data: the 25<sup>th</sup> percentile ( $Q_1$ , box bottom), median (center line, notch: 95% confidence interval (CI) for the median), and the 75<sup>th</sup> percentile ( $Q_3$ , box top); whiskers span  $[\max(x_{\min}, Q_1 - 1.5 \times IQR), \min(x_{\max}, Q_3 + 1.5 \times IQR)]$ , where  $x_{\min}$  and  $x_{\max}$  are the minimum and maximum, respectively, in the observed values and  $IQR = Q_3 - Q_1$ ;  $n = 3,747$  modules. \*\*\* $P < 0.001$  by two-sided Dunnett's test. **b–d** Comparison of DIRAC results between the LC-M001 liver proteomics and the M001-related liver transcriptomics (see Supplementary Data 6 for complete results). **b** Venn diagram of the modules that exhibited “conservatively” false discovery rate (FDR)-adjusted  $P < 0.05$  (see Methods) for the main effect of intervention on each module RCI by Analysis of Variance (ANOVA) and that exhibited significantly higher RCI in intervention group than control group (i.e., “tightened” module;  $P < 0.05$  by post hoc two-sided Student's  $t$ -tests with the Holm–Bonferroni adjustment). P: proteomics, T: transcriptomics. **c, d** Sample rank matching score (RMS) distributions for an example of the tightened modules in both proteins and transcripts (**c**; GO:0006635, fatty acid  $\beta$ -oxidation) or the tightened modules only in proteins (**d**; GO:0019441, tryptophan catabolic process to kynurenine). Data: the mean (dot) with 95% CI (bar);  $n = 12$  mice. \*\* $P < 0.01$ , \*\*\* $P < 0.001$  by two-sided Student's  $t$ -tests with the Holm–Bonferroni adjustment. **e–g** DIRAC analysis of the LC-M001 and LC-M004 liver proteomics using GOBP-defined modules (see Supplementary Data 7 for complete results). Control 1: control for Acarbose, 17 $\alpha$ -Estradiol, and Rapamycin; Control 2: control for 4EGI-1. **e** Overall distribution of module RCI. Data: each boxplot metric is the same with **a**;  $n = 153$  modules. \*\*\* $P < 0.001$  by two-sided Student's  $t$ -tests with the Holm–Bonferroni adjustment. **f** Venn diagram of the modules that exhibited nominal or “conservatively” FDR-adjusted  $P < 0.05$  (see Methods) for the main effect of intervention on each module mean of RMSs under 4EGI-1 rank consensus by ANOVA and that exhibited significantly higher mean of RMSs in intervention group than control group (i.e., “similarly” changed module to the 4EGI-1 group;  $P < 0.05$  by post hoc two-sided Student's  $t$ -tests with the Holm–Bonferroni adjustment). The number in square brackets corresponds to the similarly changed modules (nominal  $P$ -value  $< 0.05$ ). **g, h** Sample RMS distributions for an example of the

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226


1227

1228

1229

1230 similarly tightened modules (GO:0070934, coding region instability determinant (CRD)-mediated  
1231 mRNA stabilization) in proteins (**g**) or transcripts (**h**). Dashed line in **g** indicates the mean of RMSs  
1232 for the sample group corresponding to the rank consensus (i.e., RCI). Data: the mean (dot) with 95%  
1233 CI (bar);  $n = 8$  (Control-2, 4EGI-1), 12 (the others) mice.  $**P < 0.01$  by two-sided Student's *t*-tests  
1234 with the Holm–Bonferroni adjustment (**g**) or Dunnett's test (**h**).  
1235





**Figure 6. Module regulation was changed across chronological and biological ages.**

**a–g** Differential Rank Conservation (DIRAC) analysis of the Arivale plasma proteomics, with the stratified groups by chronological age (**a–d**) or  $\Delta$  age (**e–g**), using Gene Ontology Biological Process (GOBP)-defined modules (see Supplementary Data 8 for complete results). **a** Overall distribution of

1236

1237

1238

1239

1240

1241 module rank conservation index (RCI). Data: the 25<sup>th</sup> percentile ( $Q_1$ , box bottom), median (center line),  
1242 notch: 95% confidence interval (CI) for the median), and the 75<sup>th</sup> percentile ( $Q_3$ , box top); whiskers  
1243 span [ $\max(x_{\min}, Q_1 - 1.5 \times \text{IQR})$ ,  $\min(x_{\max}, Q_3 + 1.5 \times \text{IQR})$ ], where  $x_{\min}$  and  $x_{\max}$  are the minimum  
1244 and maximum, respectively, in the observed values and  $\text{IQR} = Q_3 - Q_1$ ;  $n = 19$  modules. **b** Overall  
1245 distributions of module mean of rank matching scores (RMSs) under the rank consensus of the  
1246 youngest (Q1) or oldest (Q10) group. Data: each boxplot metric is the same with **a**;  $n = 19$  modules.  
1247 *P*-value for Spearman's correlation was adjusted across sexes with the Holm–Bonferroni method. **c**  
1248 Association between module similarity to the Q1 or Q10 group and chronological age. For each  
1249 module, each rank consensus, and each sex, significance of the association was assessed using  
1250 ordinary least squares (OLS) linear regression with Body Mass Index (BMI) and ancestry principal  
1251 components (PCs) as covariates while “conservatively” adjusting multiple hypotheses with the  
1252 Benjamini–Hochberg method (see Methods). **d** An example of the significant association in **c**  
1253 (GO:0030593, neutrophil chemotaxis). In each subplot, the adjusted sample RMS with the covariates  
1254 (i.e., mean  $\pm$  residual) is plotted, and the colored line and background correspond to the OLS linear  
1255 regression line with 95% CI and the range of rank consensus group, respectively. **e** Distribution of  $\Delta$   
1256 age in the  $\Delta$  age-stratified groups (see Supplementary Fig. 4c for the chronological age distribution).  
1257 The numbers in the subplots indicate the minimum–median–maximum of each group. **f** Overall  
1258 distributions of module mean of RMSs under the rank consensus of the chronologically and  
1259 biologically youngest (Y-subQ1) or oldest (O-subQ5) group. Data: each boxplot metric is the same  
1260 with **a**;  $n = 19$  modules. Spearman's correlation was assessed for each of chronological age tertile  
1261 (CA3) groups, and its *P*-value was adjusted across CA3 groups and sexes with the Holm–Bonferroni  
1262 method. **g** Association between module similarity to the Y-subQ1 or O-subQ5 group and  $\Delta$  age. For  
1263 each module, each rank consensus, each sex, and each CA3 group, significance of the association was  
1264 assessed using OLS linear regression with chronological age, BMI, and ancestry PCs as covariates  
1265 while “conservatively” adjusting multiple hypotheses with the Benjamini–Hochberg method (see  
1266 Methods).  
1267